

CURRICULUM VITAE

RUTH A. KERI, PH.D.

PERSONAL DATA

Professional Address:

Department of Pharmacology
School of Medicine
Case Western Reserve University
2109 Adelbert Road
Cleveland, OH 44106
(216) 368-3495
FAX: (216) 368-1300
e-mail: keri@case.edu

Home Address:

10815 Kirtland Lakes Blvd.
Kirtland, OH 44094
(216) 256-2945

Place of Birth: Franklin, Pennsylvania

Education:

B.A. May, 1985, Chemistry, Edinboro University of Pennsylvania, Edinboro, PA
Ph.D. January, 1992, Pharmacology, Case Western Reserve University, Cleveland, OH

PROFESSIONAL APPOINTMENTS

2015— Inaugural Arline H. and Curtis F. Garvin M.D. and Constance C. Frackelton Professor of Cancer Research, Case Western Reserve University

2013— Professor, Department of Pharmacology, Case Western Reserve University

2013— Professor, Secondary Appointments, Division of General Medical Sciences-Oncology; Department of Genetics and Genome Sciences, Case Western Reserve University

2011— Associate Director for Basic Research, Case Comprehensive Cancer Center

2010— Vice-Chair, Department of Pharmacology, Case Western Reserve University

2010-12 Co-Director, Molecular Therapeutics Training Program, Department of Pharmacology, Case Western Reserve University

2009-13 Associate Professor, Secondary Appointment, Department of Genetics, Case Western Reserve University

2008-13 Associate Professor with Tenure, Department of Pharmacology, Case Western Reserve University

2008-13 Associate Professor, Secondary Appointment, Division of General Medical Sciences, Department of Oncology, Case Western Reserve University

1998-08 Assistant Professor, Department of Pharmacology, Case Western Reserve University

1999-08 Assistant Professor, Secondary Appointment, Ireland Cancer Center, Division of General Medical Sciences, Department of Oncology, Case Western Reserve University

2000-03 Faculty Advisor, Case Western Reserve University Transgenic Core Facility

1996-00 Director, Pharmacological Sciences Consortium Core Transgenic Facility, Case Western Reserve University

1996-98 Senior Instructor, Department of Pharmacology, Case Western Reserve University

- 1992-96 Research Associate, Department of Pharmacology, Case Western Reserve University
- 1991-92 Postdoctoral Fellow, Department of Pharmacology, Case Western Reserve University
Mentor: John H. Nilson, Ph.D.
- 1987-91 Graduate Student, Department of Pharmacology, Case Western Reserve University
Mentor: John H. Nilson, Ph.D.
- 1986-87 Research Assistant I, Department of Pharmacology, Case Western Reserve University

HONORS AND AWARDS

- Crain's Cleveland Business* Notable Women in STEM, 2019
- Faculty Distinguished Research Award, CWRU, 2017
- Department of Pharmacology Faculty Spotlight Lecture Award, CWRU, 2015
- PREP (Postbaccalaureate Research Education Program) Excellence in Mentoring Award, CWRU, 2014
- Mather Spotlight Series Prize for Women's Scholarship, CWRU, 2008
- The Department of Pharmacology, CWRU, Award for Excellence in Research, 2002
- CWRU Mortar Board "Top Prof Award", 2002
- President's Research Initiative Award, CWRU, 1999
- The Department of Pharmacology, CWRU, Award for Excellence in Teaching, 1998
- The Endocrine Society Travel Award to Attend the 80th Annual Meeting of the Endocrine Society, 1998
- The Mara E. Lieberman Travel Award for Most Promising Young Woman Investigator to the 78th Annual Meeting of The Endocrine Society, 1996
- Cellular and Molecular Biological Sciences Training Grant, GM08056, 1990-91
- Pharmacological Sciences Training Grant, GM07382, 1987-90
- American Institute of Chemists-Senior in Chemistry Award, 1985
- Beta Beta Beta-Biological Sciences Honor Society, 1985
- Alpha Chi-All College Honor Society, 1984-85
- Graduated Magna cum laude, 1985

PROFESSIONAL SERVICE OUTSIDE CWRU

National Leadership

- 2019-22 Board of Directors, at-large member, The Endocrine Society
- 2019-20 Basic Science Advisory Group, The Endocrine Society
- 2019 National Cancer Institute, Basic Science Ideas/Provocative Questions Workshop
- 2018-21 FASEB Science Policy Committee
- 2018 Governance Workshop, The Endocrine Society
- 2017 Government and Public Affairs Advisory Board for Endocrine Cancers, The Endocrine Society
- 2012-19 Research Affairs Core Committee, The Endocrine Society, **Basic Science Chair** 2015-2019
- 2010 Program Committee, **Co-Chair**, 44th Annual Meeting of the Society for the Study of Reproduction (~1,000 attendees)
- 2006 NIEHS Expert Panel, Bisphenol A: An Examination of the Relevance of Ecological, *In Vitro* and Laboratory Animal Studies for Assessing Risks to Human Health, Invited Panel Participant
- 2006 National Toxicology Program Workshop, NIEHS, Hormonally Induced Reproductive Tumors: Relevance of Rodent Bioassays, Invited Panel Participant

National Committee Membership

- 2019 Symposium Chair, *Structural and Chemical Biology of Steroid Receptors and Co-regulators*, Annual Endocrine Society Meeting
- 2019 Session Chair, *Genetics and Development of the Endocrine System in Health and Disease*, Annual Endocrine Society Meeting

- 2019 Gordon Research Conference on Hormone-Dependent Cancers, Discussion Leader for Keynote Session *Modeling of Hormone Action*
- 2018 Abstract Reviewer, 101st Annual Meeting of The Endocrine Society
- 2018-19 Gordon Research Conferences Advisory Committee for *Hormone-Dependent Cancers*
- 2013 Abstract Reviewer, 104th Annual Meeting of the American Association for Cancer Research
- 2011 Program Committee, 45th Annual Meeting of the Society for the Study of Reproduction
- 2009 Abstract Reviewer, 43rd Annual Meeting of the Society for the Study of Reproduction
- 2009 Session Chair, *Hypothalamic, Pituitary, Gonadal Axis*, 43rd Annual Meeting for the Society for the Study of Reproduction
- 2008 Abstract Reviewer, 42nd Annual Meeting of the Society for the Study of Reproduction
- 2005 Abstract Reviewer, GnRH-Gonadotropins, 87th Annual Endocrine Society Meeting
- 2004 Session Chair, *Gonadotropin-releasing Hormone & Gonadotropins: Physiology, Receptors & Cellular Mechanisms*, Endo 2004, Annual Meeting of The Endocrine Society
- 2004 Session Chair, *Gene Regulation and Function*, 37th Annual Meeting of the Society for the Study of Reproduction
- 2003-04 Program Committee for the 37th Annual Meeting of the Society for the Study of Reproduction
- 2003 Mini-Symposium Chair, *Genomic Analysis of Hormone Action*, 36th Annual Meeting of the Society for the Study of Reproduction
- 2002-03 Program Committee for the 36th Annual Meeting of the Society for the Study of Reproduction
- 2000 Session Chair, *Neuroendocrinology*, 33rd Annual Meeting of the Society for the Study of Reproduction
- 1996 Session Chair, *Gene Regulation*, 31st Annual Meeting of the Society for the Study of Reproduction

Regional Committees

- 2016, 2019 Great Lakes Breast Cancer Symposium, Program Committee
- 2015 Great Lakes Breast Cancer Symposium, **Co-Founder** and Program Committee

Journal Review Activities

- 2017-20 Associate Editor, *Endocrinology*
- 2017-22 Editorial Board, *Journal of Biological Chemistry*
- 2009-13 Editorial Board, *Biology of Reproduction*
- 2005-16 Faculty of 1000, Medicine—Environment & Women’s Health (2005-08); Oncology Agents (2008-16)
- 1997-01 Editorial Board, *Biology of Reproduction*

ad hoc Journal Reviews: *The Journal of Biological Chemistry, Molecular Endocrinology, Endocrinology, Biology of Reproduction, Mammalian Genome, Journal of Clinical Investigation, American Journal of Physiology: Cell Physiology, Genomics, Biochemical Journal, Molecular and Cellular Endocrinology, The Journal of Neuroscience, Cancer Research, Pituitary, Oncogene, Molecular Genetics and Metabolism, Carcinogenesis, European Journal of Obstetrics and Gynecology and Reproductive Biology, BMC Cancer, Clinical and Experimental Metastasis, Molecular Cancer Therapeutics, Reproduction, Development, Developmental Biology, Breast Cancer Research, Molecular Cancer Research, Nature Communications, Neoplasia, PLoS ONE, Molecular Oncology, Gene, Molecular Medicine, PLoS Genetics, Experimental and Molecular Medicine, Molecular Carcinogenesis, Frontiers in Genetics, Cancer Discovery, Nature Reviews Cancer, Journal of the National Cancer Institute, Cancer Letters, Breast Cancer Research and Treatment, Scientific Reports, EBioMedicine, Journal of Cellular Biochemistry, Cancer Biomarkers, Cellular Oncology, Frontiers in Oncology*

National/International Grant Review Panels

2019	Worldwide Cancer Research, <i>ad hoc</i> reviewer
2019	NIH/NCI, SEP, R13 Research Conference Grants, reviewer
2019	NIH/NCI, SEP, Clinical and Translational R21 and Omnibus R03, Chair
2019	NIH/NCI, P30 Site Visit Review, Fred Hutchinson Comprehensive Cancer Center
2019	NIH/NCI, SEP, Provocative Questions #10/11, Co-chair
2018	NIH, Cancer Molecular Pathobiology Study Section, <i>ad hoc</i> reviewer
2018	Breakthrough Cancer Research, Ireland, <i>ad hoc</i> grant reviewer
2018	NIH/NCI, SEP, Human Tumor Atlas Network (Cancer Moonshot), reviewer
2018	NIH/NCI, SEP, SPOREs in Breast and Ovarian Cancer, reviewer
2017	NIH/NCI, Member Conflict SEP, ZRG1 OBT-K(02), <i>reviewer</i> (twice in 2017)
2017	California Breast Cancer Research Program, reviewer
2016	NIH, SEP, Molecular Targets for Cancer Interventions [BMCT-C(01)], <i>reviewer</i>
2016	NIH/NCI, NCI I Subcommittee I –Transition to Independence Awards, <i>ad hoc</i> reviewer
2015	NIH/NCI, SEP, R21 proposals, reviewer
2011-15	NIH, Tumor Cell Biology Study Section (TCB), charter member (Co-chair 3 times)
2014	Breast Cancer Campaign UK, <i>ad hoc</i> reviewer
2014	Ohio State University Center for Clinical and Translational Science (CCTS)-Longitudinal Program grant reviewer
2013	Icelandic Research Fund, <i>ad hoc</i> reviewer
2012,13	NIH/NCI, SEP, SPOREs in Breast, Endometrial, and Skin Cancer, <i>ad hoc</i> reviewer
2011	Breast Cancer Campaign, pre-doctoral fellowship review, <i>ad hoc</i> reviewer
2011-13	Editorial Board, <i>Frontiers in Cancer Genetics</i>
2011	University of Nebraska, External Peer Review Panel, UNL Life Sciences competitive grants program
2011	American University of Beirut Faculty of Medicine Internal Grants <i>ad hoc</i> reviewer
2010	NIH, Special Emphasis Peer Review Panel, Breast Cancer and Environment Research Program Centers [ZES1 LKB-V(02)], reviewer
2010	NIH, Oncological Sciences Fellowship Review Panel (F09-A), <i>ad hoc</i> reviewer, twice in 2010
2010	NIH, SEP, Oncology I, Basic Translational, teleconference review
2009, 10	NIH, Tumor Cell Biology Study Section (TCB), <i>ad hoc</i> reviewer
2009	NIH, SEP, Reproductive Endocrinology (ZRG1 EMNR-A), reviewer
2009	NIH, SEP, Oncology Basic Translational (ZRG1 OBT-A), mail reviewer
2009	NIH/NIEHS, SEP, Children's Environmental Health and Disease Prevention Research Centers (CEHC) [ZES1 LKB-G(P1)], reviewer
2009	NIH, Integrative and Clinical Endocrinology and Reproduction (ICER), <i>ad hoc</i> reviewer
2004, 08	USAMRMC Breast Cancer Research Program, Concept Grants Review Panel, Cell Biology #3
2007	Breast Cancer Campaign, United Kingdom, Research Grant Referee
2005-06	National Cancer Institute—Canada, Program Project Review Panel
2005	USAMRMC Breast Cancer Research Program, Concept Grants Review Panel, Clinical and Experimental Therapeutics
2004-05	USAMRMC Breast Cancer Research Program, Research Grants Review Panel, Clinical and Experimental Therapeutics #1
2001-04	USAMRMC Prostate Cancer Research Program, Research Grants Review Panel, Clinical and Experimental Therapeutics #1/3
1994-95, 98-00,02,04	United States Department of Agriculture, <i>ad hoc</i> reviewer Research Proposals, Animal Reproduction; Genetic Mechanisms
2003	USDA National Research Initiative Competitive Grants Program, Peer Review Panel, Animal Reproduction Program
2003	USAMRMC Breast Cancer Research Program, Research Grants Review Panel, Pathobiology #4
2001	NIH, Biochemical Endocrinology Study Section <i>Ad hoc</i> Member

1992-93 National Science Foundation, *ad hoc* grant reviewer

Other Grant Review Service

2014 University of Nebraska-Lincoln, external pre-review for T32 submission
2005,07,09,19 Ohio Cancer Associates Grants, Peer Review Panel

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

2019— European Network for Breast Development and Cancer
2017— American Society for Biochemistry and Molecular Biology
2003— American Association for Cancer Research
2002— American Society for Pharmacology and Experimental Therapeutics
1997— Society for the Study of Reproduction
1995— The Endocrine Society
1995— American Association for the Advancement of Science

SERVICE ON MEDICAL SCHOOL AND UNIVERSITY COMMITTEES AT CWRU

University-Wide

2019 CWRU Faculty Distinguished Research Awards, Selection Committee
2017-18 Review Committee for School of Medicine Dean Reappointment
2017-19 University Faculty Senate, CWRU
2016-17 *ad hoc* Research Integrity Committee
2015 CWRU Cancer Research Fair, poster judge
2015 Research Best Practices Day, Research Misconduct Panel Discussant, CWRU
2015-17 Cleveland Center for Membrane and Structural Biology Advisory Committee
1996-97 University Committee on the Status of Women Faculty

Case Comprehensive Cancer Center (major activities)

2019— Women's Cancers Initiative, **Co-leader**
2018— Clinical Oncology Research Program (CORP), Steering Committee
2018— Case Comprehensive Cancer Center Faculty Search Committee, **Chair**
2018 Adolescent and Young Adult Cancers Research Group Internal Advisory Board
2017-19 VeloSano Pilot Grant Review Panel-Cleveland Clinic
2017 Cancer Center Strategic Plan Development
2016-17 Core grant renewal, data analytics, editing program descriptions, preparation of program leaders for site visit, facilitation of site visit presentations
2015-16 Case GI SPORE, Internal Advisory Board
2011-15 Basic Science Faculty Search Committee, **Chair**
2011— Junior Faculty Mentoring Program, **Co-leader**
2011— Pilot Grant Program, leader including **Chair** of grant review committees
2011— Seminar Series, **Director**
2011— Annual Scientific Retreat Committee
2011-2012 Core grant renewal, editing program descriptions, preparation of program leaders for site visit
2010— Tissue Utilization Advisory Board, Case Comprehensive Cancer Center
2010— Director, American Cancer Society Institutional Research Grant (pilot funding mechanism for junior faculty)
2009 Case Comprehensive Cancer Center Annual Retreat Program Committee
2009 Metastatic Breast Cancer Faculty Search Committee
2007-12 Breast Cancer Basic Science Research Group, **Co-leader**
2007-09 Tissue Procurement/Histology Advisory Committee
2007— Cancer Biology Training Program (T32), Steering Committee

2006 Prostate Pilot Grant Review Committee
 2006-10 CWRU Gene Expression and Genotyping Core Facility, Steering Committee
 2005-08 Faculty Search Committee
 2004— CWRU Institutional ACS Pilot Project Grant Peer Review Panel, 2010- **Chair**
 1999-00 Breast Cancer Working Group, Ireland Cancer Center
 2002-04 Custom Microarray Core Facility Oversight Committee
 2000-01 Gene Expression Core Facility, Advisory Board

School of Medicine

2018-19 Annual MSTP Winter Retreat Organizing Committee, **Co-Chair**
 2017-18 Search Committee for Division Chief, Hematology/Oncology, Department of Medicine, University Hospitals of Cleveland
 2017 Search Committee for Director of Biomedical Sciences Training Program (BSTP)
 2015 Great Lakes Breast Cancer Symposium, organizing committee
 2014 Urology Chair Search Committee, University Hospitals Case Medical Center
 2014-17 Multi-Disciplinary Genomics Tumor Board-Breast (University Hospitals Case Medical Center)
 2013-16 Cleveland Research Initiative Committee (CWRU and University Hospitals Case Medical Center)
 2013— Clinical Translational Science Ph.D. Training Program, Core Faculty
 2011-12 Otolaryngology Chair Search Committee, University Hospitals Case Medical Center
 2010-11 Ohio Eminent Scholar in Imaging Research, Faculty Search Committee
 2010— CWRU Heart Lung and Blood Summer Research Program Steering Committee
 2010 Case Center for Imaging Research Advisory Board
 2008— Post-baccalaureate Research Education Program (PREP) Steering Committee
 2007-10 Imaging Research Core Facility Steering Committee
 2007-15 Research Committee for the School of Medicine, Dean's Appointee
 2007-11 Interdisciplinary Biomedical Imaging Training Program in Biomedical Engineering (T32), Steering Committee
 2005-12 CWRU Transgenic and Targeting Core Facility Steering Committee, 2009-12 **Chair**
 1997,01, 02, Biomedical Sciences Graduate Student Symposium, Judge
 04,05,11-14
 2007-08 Radiology Chair Search Committee, University Hospitals of Cleveland and CWRU
 2007 Structural Biology Pilot Grant Review Committee, Case Comprehensive Cancer Center
 2006 Postdoctoral Mentoring Program Workshop—Grant Writing for Postdocs, K Award Breakout Sessions-Discussion Leader
 2005-06 IACUC Animal Resource Center Advisory Subcommittee
 2004-10 Cell and Molecular Biology Training Program Steering Committee
 2003-04 Animal Resource Center Steering Committee
 2002 University Memory and Aging Center (UMAC), Pilot Proposal Review Panel
 2000-03 CWRU Institutional Core Transgenic Facility, Steering Committee, **Chair**
 2000-06 Histology Core Facility, Steering Committee
 1996-03 Biomedical Sciences Training Program (BSTP) Admissions Committee
 1999 Animal Facility Remodeling Committee
 1997 The Irwin H. Lepow Medical Student Research Day, Judge
 1995-97 The Women's Faculty of the School of Medicine, Steering Committee

Department of Pharmacology

2018-19 Department of Pharmacology Website Development Committee, **Chair**
 2018-19 Department of Pharmacology Curriculum Reform Committee
 2016 External Review of CWRU Pharmacology: development of materials and preparation of faculty
 2016 Department of Pharmacology Strategic Planning meeting, **Co-leader**

2012 Development of Department Brochure (full color, 46 pages)
 2006— Cancer Therapeutics Track of the Molecular Therapeutics Training Program, **Co-leader**
 2006— Molecular Therapeutics Training Program (T32), Steering Committee
 2003-17 Medical Scientist Training Program (MSTP) Steering Committee
 1996-09, 16- Pharmacological Sciences Training Program (PSTP)/Molecular Therapeutics Training
 Program (MTTP) Admissions Committee (**Chair** 1996-2004, 2009)
 2006-08 Preliminary Examination I Committee—Exam Development and Grading, Pharmacology
 2006 Department of Pharmacology Strategic Planning/Facilities Committee
 2005-06, 16- Curriculum Committee
 2000-04 Pharmacological Sciences Training Program (PSTP), Steering Committee
 1997-03 Space Committee
 1998-01 Faculty Search Committee
 1998-01 Retreat Committee
 1997-98 Preliminary Examination Restructuring Committee, **Chair**
 1997 Development of Department Student Recruitment Poster/Mailers
 1996-03 Director of Admissions, Pharmacology Training Program

PAST AND PRESENT TEACHING ACTIVITIES

Lecturer and Computer Lab Developer in International Course

2004-10 Frontiers in Reproduction
 Topics: Bioinformatics in Molecular Endocrinology; Mechanisms of Breast Cancer
 Lecturer/Laboratory Instructor/Content Development/Production of Course Materials
 8 contact hours/year (2 hours lecture, 6 hours laboratory), ~20 graduate students and
 fellows/year
 Marine Biological Laboratory, Woods Hole, MA

Lectures and Discussion Group Leader in Graded Courses at CWRU

2015-19 Grant Writing Workshop
 Content Development
 3 contact hours, 6-8 graduate students
 Department of Pharmacology

2010 Cellular and Molecular Imaging, EBME462
 Topic: Introduction to Cancer Biology
 Lecture/Content Development
 1.25 contact hours
 School of Engineering

2009-14 Block 4, Western Reserve2
 Topic: Personalized Medicine
 Lecture/Content Development
 2.5 contact hours, ~120 medical students
 School of Medicine

2009-10 Block 4, Western Reserve2
 Topic: Pharmacodynamics
 Small Group Discussion Leader
 1.5 contact hours, ~40 medical students
 School of Medicine

2008 Block 4, Western Reserve2
 Topic: Pharmacogenetics and Genomics of Asthma Therapy
 Lecture/Team Based Learning (TBL)/Content Development
 2 contact hours, ~120 medical students for lecture and ~40 medical students for TBL

- School of Medicine
- 2008 Classic and Contemporary Approaches in Drug Discovery
Topics: Mouse Models and Genetic Approaches for Target Validation/Gene Expression Arrays
Lecture/Content Development/Exam Development/Grading
3 contact hours, ~15 graduate students
Department of Pharmacology
- 2007 Basic Science Correlations
Topic: Genetic Contributions to Breast Cancer Outcome
Lecturer/Content Development
1 contact hour, ~70 medical students
School of Medicine
- 2007 Basic Science Correlations
Topic: Genetic Contributions to Breast Cancer Outcome
Lecturer/Small Group Discussion Leader/Content Development
2 contact hours, ~40 students
School of Medicine
- 2007 Block 4, Western Reserve2
Topic: Pharmacogenetics
Group Discussion Leader/Content Development
2 contact hours, ~120 medical students
School of Medicine
- 2006-14 Principles of Pharmacology I: The Physiological Basis of Therapeutics, PHRM401
Topic: Pharmacogenetics
Lecturer/Discussion Leader/Content Development/Exam Development and Grading
3 contact hours, 4-8 graduate students
Department of Pharmacology
- 2006-2018 Principles of Pharmacology II: The Molecular Basis of Therapeutics, PHRM402
Topic: Cancer-targeted Therapies
Lecturer/Discussion Leader/Content Development/Exam Development and Grading
3 contact hours, 4-10 graduate students
Department of Pharmacology
- 2006,08-10 Molecular Genetics of Cancer, BIOC420
Topics: Mouse Models of Breast Cancer and Breast Cancer Stem Cells
Lecturer/Discussion Leader/Content Development
4 contact hours, ~15 graduate students
Department of Biochemistry
- 2002-10 Correlated Curriculum in Cell and Molecular Biology, CBIO453
Topics: Methods in Molecular Biology (Microarrays, Transgenic Technology, Transfections, Blotting)
Lecturer/Content Development/Exam Development and Grading
3-4 contact hours/year, ~45-60 graduate students/year
Biomedical Sciences Training Program
- 2001-05 Core Academic Program—Fundamentals of Therapeutics Committee, PHRM421
Topic: Pharmacogenetics and Pharmacogenomics
Lecturer and Small Group Discussion Leader/Content Development including developing and writing small group discussion exercise/Exam Development
13 contact hours (1 hr lecture, 12 hr small group)/year, ~140 medical and ~6 graduate students/year
School of Medicine

1996,98,00,03,05 Endocrine Pharmacology, PHRM515
 Topics: Female Reproduction, Hypothalamic/Pituitary/Gonadal Axis
 Lecturer/Discussion Leader/Content Development/Assessment of Student Presentations
 6 contact hours/course year, 4-6 graduate students/year
 Course Director: 1998, 2000; Responsible for Content Development, Identifying and Coordinating Faculty and Grading
 16 contact hours/course year, 4-6 graduate students/year
 Department of Pharmacology

1997-04 Molecular Pharmacology/Molecular and Genomic Pharmacology, PHRM413
 Topics: Receptor/Effector Coupling at the Organismal Level; Pharmacogenomics and Genetics
 Lecturer/Discussion Leader/Content Development, Exam Development and Grading
 6 contact hours/year, 6-12 graduate students/year
 Department of Pharmacology

2002 Core Academic Program—Drug Action and Biodisposition Committee, PHRM423
 Topic: Asthma Medications
 Small Group Discussion Leader/Content Development
 8 contact hours, ~140 medical students, ~6 graduate students
 School of Medicine

1989-98,2000-02 Core Academic Program—Fundamentals of Therapeutics Committee, PHRM421
 Topic: Cardiovascular Pharmacology
 Lab Instructor
 6 contact hours/year, 8-10 medical students/year
 School of Medicine

2001 Core Academic Program—Endocrine Committee
 Topic: Adrenal Gland
 Small Group Discussion Leader
 2 contact hours, ~20 medical students
 School of Medicine

2001 Cancer Biology and Therapeutics, PHRM520
 Topic: Hormones and Cancer, Transmembrane Receptors
 Lecturer/Content Development/Exam Development
 1.5 contact hours, 16 graduate students
 Department of Pharmacology

2001 Molecular Therapeutics, Correlated Curriculum in Cell and Molecular Biology, CBIO455
 Topic: HER2-Targeted Therapy in Breast Cancer
 Lecturer/Discussion Leader/Content Development/Assessment of Student Presentations
 3 contact hours, 20 graduate students
 Biomedical Sciences Training Program

1998-99 Dental Pharmacology, DEND242
 Topic: Endocrine Pharmacology
 Lecturer/Content Development/Exam Development
 4 contact hours/year, ~70 dental students/year
 School of Dentistry

1998-99 Dental Pharmacology, Board Exam Review, DEND242
 Topic: Endocrine Pharmacology
 Lecturer/Discussion Leader
 1 contact hour/year, ~70 dental students/year
 School of Dentistry

- 1998 Core Academic Program—Endocrine Committee
Topic: Pituitary
Small Group Discussion Leader
4 contact hours, ~40 medical students
School of Medicine
- 1997 Core Academic Program—Drug Action and Biodisposition Committee
Topic: Breast Cancer Therapeutics
Small Group Discussion Leader
2 contact hours, ~20 medical students
School of Medicine
- 1993-96 Core Academic Program—Endocrine Committee
Topic: G-proteins
Small Group Discussion Leader
2 contact hours/year, ~20 medical students/year
School of Medicine

On-Line Curriculum Development

- 2008-09 Development of PharmWeb Modules for Blocks 2/3 of Western Reserve2
Topics: Drug Delivery, Receptor Regulation, Pharmacogenetics, Pharmacokinetic
Pharmacogenetics
Content Development
~150 medical students

CWRU Thesis and Pre-thesis Committees

- 2019- Jennifer Castrillon, Pre-Thesis Committee, **Chair**, Molecular Medicine, Cleveland Clinic
- 2019- Hannah Hill, Pre-Thesis Committee, Department of Pharmacology
- 2017-18 Brendan Barton, Pre-Thesis Committee, Department of Pathology
- 2017-18 Daniel Leonard, Pre-Thesis Committee, Molecular Medicine, Cleveland Clinic
- 2016-17 Jennifer Bell, Pre-Thesis Committee, Department of Pathology
- 2016- Leslie Cuellar-Vite, Pre-Thesis Committee, Department of Pharmacology, Advisor
- 2016- Bryan Webb, Pre-Thesis Committee, Department of Pharmacology, Advisor
- 2016-19 Alyssa LaBelle, Pre-Thesis Committee, Department of Pharmacology
- 2016- Xu Han, Pre-Thesis Committee, Department of Pharmacology
- 2015- Stetson Thacker, Pre-Thesis Committee, Molecular Medicine, Cleveland Clinic
- 2015-19 Caitlin O'Connor, Pre-Thesis/Thesis Committee, Department of Pharmacology
- 2015- Wilnelly Hernandez-Sanchez, Pre-Thesis Committee, **Chair**, Depart. Pharmacology
- 2015- Valery Adorno-Cruz, Pre-Thesis Committee, **Chair**, Department of Pharmacology
- 2015-19 Matthew Knarr, Pre-Thesis/Thesis Committee, **Chair**, Department of Pharmacology
- 2015-16 Josh Miller, Pre-Thesis/MS Thesis Committee, **Chair**, Department of Pharmacology
- 2015- Elizabeth Akinbiyi, Pre-Thesis Committee, Department of Pathology
- 2014- Darcie Seachrist, Pre-Thesis Committee, Department of Pharmacology, Advisor
- 2014-18 Jennifer Sahni, Pre-Thesis/Thesis Committee, Department of Pharmacology, Advisor
- 2014- Caroline Farrington, Pre-Thesis Committee **Chair**, Department of Pharmacology
- 2013-16 Kevin Huynh, Pre-Thesis/Thesis Committee, Department of Pharmacology
- 2013-17 Danica Wiredja, Pre-Thesis/Thesis Committee, Systems Biology and Bioinformatics
- 2013-17 Lamis Yehia, Pre-Thesis/Thesis Committee, Department of Pathology
- 2013-17 Courtney Bartel, Pre-Thesis/Thesis Committee, Department of Pathology
- 2012-16 James Morrow, Pre-Thesis/Thesis Committee, Department of Pathology
- 2012-13 Joseph Myers, Pre-Thesis Committee, Department of Biomedical Engineering
- 2012-16 Andrea Cohen, Pre-Thesis/Thesis Committee, Department of Genetics
- 2011-16 Karin Lee, Pre-Thesis/Thesis Committee, Department of Biomedical Engineering
- 2011-16 Andrea Boyd-Tressler, Pre-Thesis/Thesis Committee **Chair**, Department of Pharmacology

2011-14 Emily Nizialek, Pre-Thesis/Thesis Committee, Department of Genetics
2010-12 Molly Taylor, Pre-Thesis/Thesis Committee, Department of Pharmacology
2010-15 Maricruz Rivera, Pre-Thesis/Thesis Committee, **Chair**, Mol. Medicine, Cleveland Clinic
2010-15 Kuo-Sheng Hsu, Pre-Thesis Committee, Department of Biochemistry
2009-13 Jennifer Zechel, Pre-Thesis/Thesis Committee, Department of Genetics
2008-13 Lachelle Weeks, Pre-Thesis/Thesis Committee, Department of Pathology
2008 Kristopher Stanya, Ph.D. Thesis Defense Committee, Department of Biochemistry
2007-10 Vicki Nelson, Pre-Thesis/Thesis Committee, Department of Genetics
2007-08 Jennifer Leising, Pre-Thesis Committee, Department of Pharmacology
2007-10 Tianyi Krupka, Pre-Thesis/Thesis Committee, Department of Biomedical Engineering
2007-10 Ravi Patel, Pre-Thesis/Thesis Committee, Department of Biomedical Engineering
2006-07 Linnea Patt, Pre-Thesis/Thesis Committee, **Chair**, Department of Pharmacology
2006-11 Gina Bernardo, Pre-Thesis/Thesis Committee, Department of Pharmacology, Advisor
2005-06 Kate Webber, Pre-Thesis/Thesis Committee, Department of Pathology
2004-09 Xiaoxue Zhang, Pre-Thesis/Thesis Committee, Department of Pharmacology
2004-08 Smitha Sripathy, Pre-Thesis/Thesis Committee, **Chair**, Department of Pharmacology
2004-08 Tara Ellison, Pre-Thesis/Thesis Committee, Department of Pharmacology
2004-07 Brent Weinberg, Pre-Thesis Committee, Department of Biomedical Engineering
2004-06 Dolly Padovani-Claudio, Pre-Thesis/Thesis Committee, Department of Neurosciences
2004-06 Sheila Cherry, Pre-Thesis/Thesis Committee, Department of Genetics
2004-10 Jennifer Yori, Pre-Thesis Committee, Department of Pharmacology, Advisor
2004-09 Marjorie Montanez-Wiscovich, Pre-Thesis/Thesis Committee, Depart. Pharm., Advisor
2003 Chi Zhang, Ph.D. Thesis Defense Committee, Department of Pharmacology
2003-04 Vonya Miksic, M.S. Pre-Thesis Committee, Department of Biomedical Engineering
2003-06 Tehnaz Parakh, Pre-Thesis/Thesis Committee, **Chair**, Department of Pharmacology
2003-07 Jonathan Mosley, Pre-Thesis/Thesis Committee, Department of Pharmacology, Advisor
2002-06 Martha Susiarjo, Pre-Thesis/Thesis Committee, Department of Genetics
2001-03 Brenda Altose, Pre-Thesis Committee, **Chair**, Department of Pharmacology
2001-04 Michael Malone, Pre-Thesis/Thesis Committee, Department of Pharmacology
2001-04 Bethany Cruise, Pre-Thesis/Thesis Committee, Department of Neurosciences
2001-06 Samantha Cicero, Pre-Thesis/Thesis Committee, Department of Pharmacology
2001-05 Melissa Landis, Pre-Thesis/Thesis Committee, Department of Pharmacology, Advisor
2001-05 Erin Milliken, Pre-Thesis/Thesis Committee, Department of Pharmacology, Advisor
2000-04 Helai Mohammad, Pre-Thesis/Thesis Committee, Department of Pharmacology
1999-02 Gabe Owens, Pre-Thesis/Thesis Committee, Department of Pharmacology
1998 Rachel Mann, Ph.D. Thesis Defense Committee, Department of Pharmacology

External University Thesis Committees

2014-17 Andrea Hindman, Ph.D. Pre-Thesis/Thesis Committee, Molecular, Cellular, and Developmental Biology, The Ohio State University
2012 Raheleh Hatami, Ph.D. Thesis Defense Committee, Mount Sinai Graduate School of Biological Sciences

Seminars at CWRU

2018 K12 Career Development Series
Topic: Development of Specific Aims Pages for Grants
5 Physician Scientist Trainees
2016 MSTP Faculty Seminar
Topic: Career Development and Analysis of Therapeutics for Breast Cancer
~20 Trainees

- 2013 Department of Biomedical Engineering
Topic: Regulation of Breast Cancer Phenotypes
Lecture/Content Development
~40 Faculty/Trainees
- 2013 Case Comprehensive Cancer Center Seminar Series
Topic: Regulation of Breast Cancer Phenotypes
Lecture/Content Development
~100 Faculty/trainees
- 2012 Tumor Microenvironment Mini-Retreat/Cancer Center
Topic: Follistatin and Breast Cancer Metastasis
Lecturer/Content Development
~50 Faculty
- 2011 Department of Biomedical Engineering
Topic: Protein, RNA, and DNA Detection Methods
Lecturer/Content Development
~25 graduate students/faculty
School of Engineering
- 2009 Department of Genetics
Topic: Functional Genomics of Mammary Gland Development and Cancer
Lecturer/Content Development
~50 graduate students/faculty
School of Medicine
- 2009 Pathology Grand Rounds
Topic: Functional Genomics of Mammary Gland Development and Cancer
Lecturer/Content Development
~40 residents/fellows/faculty
School of Medicine/University Hospitals of Cleveland
- 2008 Department of Biochemistry Seminar Series
Topic: Functional Genomics of Breast Development and Cancer
Lecturer/Content Development
~75 graduate students/faculty
School of Medicine
- 2007 Blood Club
Topic: Using animal models and human gene expression data to identify mechanisms of breast carcinogenesis
Lecturer/Content Development
~75 graduate students/fellows/residents/faculty
Case Comprehensive Cancer Center
- 2007 Department of Biochemistry Seminar Series
Topic: Identifying mechanisms underlying HER2/Neu-induced breast cancer
Lecturer/Content Development
~50 graduate students/fellows/faculty
School of Medicine
- 2007 Cell and Molecular Biology Training Program Trainer Seminar Series
Topic: Using animal models and human gene expression data to identify mechanisms of breast carcinogenesis
Lecturer/Content Development
~20 graduate students/faculty
School of Medicine

- 2006 Department of Anatomy Seminar Series
 Topic: Using microarray analyses to identify pathways and therapeutic strategies for
 HER2/Neu-induced mammary tumors
 Lecturer/Content Development
 ~20 graduate students/fellows/faculty
 School of Medicine
- 2006 Department of Pharmacology Seminar Series
 Topic: Identifying mechanisms underlying HER2/Neu-induced breast cancer and their
 potential use for targeted therapy
 Lecturer/Content Development
 ~50 graduate students/fellows/faculty
 School of Medicine
- 2004, 07 Pediatric Pulmonary Fellows Course
 Topic: Overview of Transgenic Animals
 Lecturer/Content Development
 4-5 fellows
 School of Medicine
- 2003 Medical Scientist Training Program Annual Summer Retreat
 Topic: An Introduction to Transgenic Technology
 Lecturer/Content Development
 ~50 MSTP students and faculty
 School of Medicine
- 2003 Department of Ophthalmology Retreat
 Topic: Transgenic Mice
 Lecturer/Content Development
 ~40 graduate students/faculty
 School of Medicine
- 2003 Medical Scientist Training Program Dinner Seminar Series
 Topic: Using Functional Genomics to Identify Candidate Genes
 Involved in Hormone-Induced Breast Cancer
 Lecturer/Content Development
 ~20 MSTP students
 School of Medicine
- 2002 Research Oncology Training Program
 Topic: Coupling transgenic mouse models with functional genomics to study hormone-
 induced breast cancer
 Lecturer/Content Development
 ~15 graduate students/fellows/faculty
 Ireland Cancer Center
- 2002 Department of Pathology Seminar Series
 Topic: Coupling transgenic mouse models with functional genomics to study hormone-
 induced breast cancer
 Lecturer/Content Development
 ~50 graduate students/fellows/faculty
 School of Medicine

- 2002 Department of Genetics Seminar Series
Topic: Mouse models of mammary cancer: Using transcriptome analyses to gain new insights into mammary gland development and cancer
Lecturer/Content Development
~75 graduate students/fellows/faculty
School of Medicine
- 2001 Department of Pediatrics Research Seminar
Topic: Coupling transgenic mouse models with gene expression array technology to identify mechanisms underlying mammary gland carcinogenesis
Lecturer/Content Development
~20 graduate students/fellows/faculty
School of Medicine
- 2001 Blood Club
Topic: Mouse Models of Mammary Cancer: New Insights Gained Through Gene Expression Profiling
Lecturer/Content Development
~75 graduate and medical students/fellows/residents/faculty
Ireland Cancer Center
- 2000 Research Oncology Training Program
Topic: Using a Mouse Model of Ovarian Hyperstimulation to Understand the Hormonal Basis of Breast Cancer
Lecturer/Content Development
~15 graduate students/fellows/faculty
Ireland Cancer Center
- 1998 Endocrine Grand Rounds
Topic: From Pituitary to Ovary: Using Transgenic Mice to Study the Expression and Function of Luteinizing Hormone
Lecturer/Content Development
~20 medical students/residents/fellows/faculty
School of Medicine
- 1998 Minority Medical Student Lecture Series
Topic: Transgenic Mice
Lecture/Content Development
4 medical students
Skin Diseases Research Center, School of Medicine

Invited External Presentations

1. Transgenic Technology in Medicine and Agriculture Meeting, National Institutes of Health. 1988. Keri, R.A., Bokar, J.A., Farmerie, T.A., Fenstermaker, R.A., Andersen, B.A., Yun, J., Wagner, T., and Nilson, J.H. "Functional comparison of the promoter regulatory elements of the human and bovine alpha subunit genes: different cis-active elements are required for pituitary and placental expression."
2. Department of Biology Seminar Series, Kent State University. 1996. "Expression of the bovine luteinizing hormone beta subunit gene: using transgenic mice to study an elusive promoter."
3. Alzheimer's Disease Center Seminar Series, Mayo Clinic Jacksonville. 1997. "Expression of the bovine luteinizing hormone beta subunit gene: using transgenic mice to study an elusive promoter."
4. Department of Physiology Seminar Series, Colorado State University. 1998. "Expression of LH and Tumors. Can You Have Too Much of a Good Thing?"
5. Department of Biology Colloquium, University of Akron. 2000. "Ovarian Hyperstimulation and Cancer: What Happens When Good Hormones Go Bad."

6. United States Biochemical Corporation, 2000. "Using functional genomics to understand the hormonal basis of mammary cancer in transgenic mice"
7. Department of Biology Seminar Series, Kent State University, 2002. "Transgenic Technology: An Approach for Modeling Human Breast Cancer in Mice."
8. Colorado State University, Animal Reproduction and Biotechnology Laboratory, 2003. "Using Functional Genomics to Identify Candidate Genes Involved in Hormone-Induced Breast Cancer."
9. Washington State University, School of Molecular Biosciences, 2003, "Using Functional Genomics to Identify Candidate Genes Involved in Hormone-Induced Breast Cancer."
10. Annual Meeting of the Society for the Study of Reproduction, Vancouver, Canada, 2004, "Ovary Function and Breast Disease", Mini-symposium--Mouse Models and Gonadal Physiology—New Inroads.
11. Ohio State University, School of Pharmacy, 2004, "Using functional genomics to identify candidate genes involved in hormone and growth-factor-induced breast cancer."
12. NIH/NCI, Activities to Promote Research Collaborations Workshop for APCR Funded Proposals, 2005, "Early detection and therapeutic assessments using small animal imaging approaches in mouse models of breast cancer."
13. Rammelkamp Research Conferences, MetroHealth Medical Center, 2007, "Using animal models and human gene expression data to identify mechanisms of breast carcinogenesis."
14. Cleveland Clinic Lerner Research Institute, Department of Molecular Genetics, 2007, "Mechanisms of HER2/Neu-induced breast cancer"
15. Cornell University College of Veterinary Medicine, Department of Reproductive Biology, 2008, "Functional Genomics of Breast Development and Cancer"
16. University of Nebraska Medical Center, Department of Genetics, Cell Biology, and Anatomy, 2009, "Functional Genomics of Breast Development and Cancer"
17. University of Toledo, School of Pharmacy, Department of Pharmacology, 2009, "Functional Genomics of Breast Development and Cancer"
18. Cleveland Clinic Lerner Research Institute, Department of Cell Biology, 2009, "Functional Genomics of Breast Development and Cancer"
19. Cleveland Clinic Lerner Research Institute, Department of Cancer Biology, 2011, "Identification of Novel Pathways Involved in Breast Development and Cancer"
20. University Hospitals Seidman Cancer Center, Imaging Solutions in Cancer Management: A Case Based Conference, 2011, "Preclinical Development and Utilization of Breast Imaging"
21. Ohio State University Comprehensive Cancer Center Molecular Biology-Cancer Genetics Program, 2011, "Forkhead Transcription Factor Regulation of Breast Cancer Phenotypes"
22. Michigan State University, Department of Physiology Seminar Series, 2012, "Forkhead Transcription Factor Regulation of Breast Cancer Phenotypes"
23. Endocrine Society Annual Meeting, Symposium Presentation, 2012, "Forkhead Transcription Factor Control of Breast Epithelial Cell Phenotypes", Symposium: Putting the Brakes on Breast Cancer
24. Temple University, Fels Institute for Cancer Research and Molecular Biology Seminar Series, 2013, "Regulation of Breast Cancer Phenotypes"
25. Mayo Clinic Cancer Center-Jacksonville Seminar Series, 2013, "Regulation of Breast Cancer Phenotypes"
26. Cedars-Sinai Medical Center, Women's Cancer Program Seminar Series, 2014, "Transcriptional Regulation of Breast Cancer Phenotypes"
27. Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Biology of Cancer Course, 2015, "Transcriptional Control of Epithelial Cell States"
28. Endocrine Society Annual Meeting, Symposium Presentation 2016, "BET Protein Inhibitors in Triple Negative Breast Cancer"

29. Gordon Conference on Hormone Dependent Cancers, 2017, "Targeting Mitosis-Associated Gene Expression in Breast Cancer"
30. Cleveland Clinic Department of Cancer Biology Seminar Series, 2017, "Mechanisms of Therapeutic Response and Resistance in Breast Cancer"
31. Indiana University School of Medicine, 2018, "Mechanisms of Therapeutic Response in Breast Cancer"
32. University of Pittsburgh Cancer Institute, 2018, "Mechanisms of Therapeutic Response in Breast Cancer"
33. University of Colorado Department of Pathology, 2018, "Mechanisms of Therapeutic Response in Breast Cancer"
34. Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 2018, "Novel Breast Cancer Therapies"
35. University of Wisconsin, McArdle Laboratory for Cancer Research, 2018 "Mechanisms of Therapeutic Response in Breast Cancer"
36. University of Illinois at Chicago, Department of Physiology and Biophysics, 2018, "Mechanisms of Therapeutic Response in Breast Cancer"
37. University of Wisconsin, Department of Cell and Regenerative Biology, 2018, "From Mammary Morphogenetic Mechanisms to Breast Cancer Targeted Therapies"
38. Virginia Commonwealth University, Department of Pathology, 2018, "Mechanisms of BET Inhibitor Action in Triple Negative Breast Cancer"
39. Endocrine Society Annual Meeting, Symposium Presentation, 2019, "Epigenetic Targeting of Triple Negative Breast Cancer"

Faculty Mentorship Committees

- 2019— Megan Miller, Assistant Professor, Surgical Oncology, University Hospitals Cleveland Medical Center
- 2017— Travis Salisbury, Assistant Professor, Marshall University
Mentored project supported by NIH P20 GM121299 COBRE: "Appalachian Center for Cellular Transport in Obesity Related Disorders (ACCORD)" Research Project: Inhibition of leucine-stimulated induction of mTOR1 to suppress breast cancer in obesity
- 2015-19 Eli Bar, PhD, Assistant Professor, Neurological Surgery, CWRU
- 2015— Vinay Varadan, PhD, Assistant Professor, Case Comprehensive Cancer Center
- 2015-17 Shaveta Vinayak, MD, Assistant Professor, Medicine, CWRU
- 2015— Reshmi Parameswaran, Ph.D., Instructor, Pathology, CWRU
- 2014— Stefanie Avril, M.D., Assistant Professor, Pathology, CWRU
- 2014-17 Kristian Baker, Ph.D., Associate Professor (promoted to Associate Professor), RNA Center, CWRU
- 2014-18 Analisa DiFeo, Ph.D., Assistant Professor (promoted to Associate Professor), General Medical Sciences-Oncology, CWRU
- 2014-16 Huiping Liu, M.D., Ph.D., Assistant Professor, Pathology, CWRU
Mentored project for Susan G. Komen Career Catalyst Research Grant
- 2014-17 Cheryl Thompson, Ph.D., Assistant Professor, Family Medicine, CWRU
- 2013-18 Marcin Golczak, Ph.D., Assistant Professor, Pharmacology, CWRU
- 2012-16 Vera Moiseenkova-Bell, Ph.D., Assistant Professor (promoted to Associate Professor), Pharmacology, CWRU
- 2012-17 Junran Zhang, M.D., Ph.D., Assistant Professor, Radiation Oncology, CWRU
- 2011-13 Saba Valadkhan, Ph.D., Assistant Professor, RNA Center, CWRU
- 2011-17 Nicole Steinmetz, Ph.D., Assistant Professor (promoted to Associate Professor), Biomedical Engineering, CWRU
Mentored project for Susan G. Komen Career Catalyst Research Grant

- 2011-17 Marvin Nieman, Ph.D., Assistant Professor (promoted to Associate Professor),
Pharmacology, CWRU
- 2010-17 Barbara Bedogni, Ph.D., Assistant Professor (promoted to Associate Professor),
Biochemistry, CWRU
- 2009-17 Derek Taylor, Ph.D., Assistant Professor (promoted to Associate Professor),
Pharmacology, CWRU
- 2009-16 Youwei Zhang, Ph.D., Assistant Professor (promoted to Associate Professor),
Pharmacology, CWRU

Trainees

Post-doctoral Fellows

- 2019— **Benjamin Bryson**, Ph.D., Case Western Reserve University, 2017
- 2017— **Lindsey Anstine**, Ph.D., The Ohio State University, 2016
Awards: Research Oncology Training Grant, Post-doctoral Trainee, 5T32CA059366, 2017-18; DoD BCRP Breakthrough Fellowship Award, W81XWH-18-1-0455, 2018-21; Outstanding Oral Presentation Award Department of Pharmacology Annual Retreat, 2018; First Place, Post-doctoral Poster Presentation, Research ShowCASE, 2019.
- 2016— **Elyse Donabauer**, Ph.D., Washington State University, 2016
Awards: First Place, Post-doctoral Poster Presentation, Research ShowCASE, 2019
- 2013-18 **Sylvia Shabaya Gayle**, Ph.D., Emory University, 2013
Awards: Research Oncology Training Grant, Post-doctoral Trainee, 5T32CA059366, 2013-15; Oral Presentation Award, Department of Pharmacology Annual Retreat; Travel Award to Gordon Conference on Mammary Gland Biology, 2015; AACR Scholar-in-Training Award to attend the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, 2016; FASEB/MARC Travel Award to the 2016 Postdoctoral Preparation Institute Workshop; First-Place, Research ShowCase Post-doc Award for outstanding research poster presentation, 2016; Poster Presentation Award-Case Comprehensive Cancer Center Annual Scientific Retreat, 2016; Post-doc of the Year Award, Department of Pharmacology, 2016, Outstanding Poster Presentation Award, Department of Pharmacology Annual Retreat, 2016, Recipient of NRSA Post-doctoral Fellowship (1F32CA210426); Honorable Mention, CWRU Research Showcase Post-doc Poster Presentation, 2017. Outstanding Poster Presentation Award, Department of Pharmacology Annual Retreat, 2017.
Current Position: Scientific Program Analyst, NCI Center for Biomedical Informatics and Information Technology (CBIIT) and Office of Data Sharing (ODS)
- 2011-15 **Jennifer Yori**, Ph.D., Case Western Reserve University, 2011
Awards: Best Oral Presentation, Department of Pharmacology Retreat, 2012
Current Position: Medical Science Liaison, Calithera Biosciences
- 2011-12 **Gina Bernardo**, Ph.D., Case Western Reserve University, 2011
Current Position: Assistant Professor, Dept. Radiation Oncology, The Ohio State University
- 2009-11 **Melissa Shelton**, Ph.D., Case Western Reserve University, 2008
Awards: Department of Defense USAMRMC Post-doctoral Fellowship, W81XWH-09-1-0558, 2009-2011
Current Position: Research Associate, Cleveland VA Medical Center

- 2008-12 **Steve Sizemore**, Ph.D., Kent State University, 2008
 Awards: Research Oncology Post-doctoral Trainee, 5T32CA059366, 2008-09;
 Department of Defense USAMRMC Post-doctoral Fellowship, W81XWH-
 09-1-0696, 2009-2012
 Current Position: Assistant Professor, Dept. Radiation Oncology, The Ohio
 State University
- 2006-10 **Emhonta Johnson**, Ph.D., University of Toledo, 2003
 Awards: Research Oncology Post-doctoral Trainee, 5T32CA059366, 2006-
 2007; Post-doc of the Year Award, Department of Pharmacology, 2008;
 Outstanding Poster Award for post-doctoral fellows, Research ShowCASE,
 CWRU, 2009; Susan G. Komen Scholar-in-Training Travel Award to AACR
 100th annual meeting, 2009.
 Current Position: Professor, Dept. Biology, Cuyahoga Community College

Ph.D. Students

- 2018- **Katrina Piemonte**, MD, PhD student, Department of Pharmacology
 Thesis Project: GAS2L3 regulation of chromosomal instability in triple negative
 breast cancer.
- 2018- **Parth Majmudar**, Department of Pharmacology
 Thesis Project: Mechanisms of PRMT5 inhibitor resistance in breast cancer
 Awards: Molecular Therapeutics Training Program Trainee, T32GM008803,
 2018-2020
- 2016- **Melyssa Shively**, Department of Pharmacology
 Thesis Project: LIN9 modulation of taxol sensitivity in breast cancer
 Awards: Outstanding Poster Presentation Award, Department of Pharmacology
 Annual Retreat, 2016; Outstanding Oral Presentation Award, Department
 of Pharmacology Annual Retreat, 2017; Outstanding Poster Presentation
 Award, Biomedical Graduate Student Symposium, 2018; Case
 Comprehensive Cancer Center Trainee Travel Award to AACR annual
 meeting, 2019; First-Place Graduate Student Poster Presentation,
 Research ShowCASE, 2019.
- 2015- **Bryan Webb**, MD, PhD student, Department of Pharmacology
 Thesis Project: Mechanisms of CDK7 inhibitor action and resistance in triple
 negative breast cancer.
 Awards: Molecular Therapeutics Training Program Trainee, T32GM008803,
 2016-2017; Recipient of F31 Pre-doctoral Fellowship (F31CA224809),
 2017-19; Outstanding Poster Presentation Award, Case Comprehensive
 Cancer Center Annual Retreat, 2017; Outstanding Poster Presentation
 Award, Department of Pharmacology Annual Retreat, 2017; Outstanding
 Poster Presentation, MSTP Annual Retreat, 2019; First Place Graduate
 Student Poster Presentation, Research ShowCASE, 2019; First Prize, Oral
 Presentation Award, Great Lakes Breast Cancer Symposium, 2019.
- 2015- **Leslie Cuellar Vite**, Department of Pharmacology
 Thesis Project: Modulation of mTOR feedback pathways for the treatment of
 breast cancer.
 Awards: Cell and Molecular Biology Training Grant T32GM008056, 2016-18;
 Scholarship to attend "Short Course on Experimental Models of Human
 Cancer" at the Jackson Laboratory, 2016; Graduate Student Appreciation
 Award, CWRU SOM, 2017; PREP Alumni Award, CWRU, 2017;
 Outstanding Oral Presentation Award, Department of Pharmacology
 Annual Retreat, 2018; Honorable Mention Poster Presentation Award,

Great Lakes Breast Cancer Symposium, 2019; Graduate Student Appreciation Award, CWRU SOM, 2019; CWRU SOM Student Leadership Award, 2019.

- 2014- **Darcie Seachrist**, Department of Pharmacology
Thesis Project: Identifying the role of BCL11A in triple negative breast cancer.
Awards: Greenfield Family Travel Award (for best Journal Club of 14/15 school year in Pharmacology at CWRU), 2015; Poster Presentation Award, Case Comprehensive Cancer Center Annual Scientific Retreat, 2016; Outstanding Oral Presentation Award, Department of Pharmacology Retreat, 2016; First Place, CWRU Research Showcase Graduate Student Poster Presentation, 2017. Outstanding Poster Presentation Award, Department of Pharmacology Annual Retreat, 2017; Outstanding Poster Presentation Award, Case Comprehensive Cancer Center Annual Scientific Retreat, 2018; Outstanding Poster Presentation Award, Department of Pharmacology Annual Retreat, 2018; 2nd Place Oral Presentation Award, Biomedical Graduate Student Symposium, 2018; Case Comprehensive Cancer Center Trainee Travel Award to Gordon Research Conference on Hormone Dependent Cancers, 2019.
- 2013-18 **Jennifer Brancato Sahni**, Department of Pharmacology
Thesis Project: Assessing the function of BET proteins in triple negative breast cancer.
Awards: Cancer Biology Training Grant Pre-doctoral Trainee, 5T32CA059366, 2013-15; Oral Presentation Award, Department of Pharmacology Annual Retreat, 2013; Poster Presentation Award, Department of Pharmacology Annual Retreat, 2014; Selected Oral Presentation, Gordon Conference on Mammary Gland Biology, 2015; Graduate Student Appreciation Award (for contributions that improve the CWRU campus and Cleveland communities), 2016; AACR-Triple Negative Breast Cancer Foundation Scholar-in-Training Award, 2016; Recipient of NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award (1F99CA212460), 2016: Outstanding Poster Award, Department of Pharmacology Annual Retreat, 2016: Graduate Student of the Year, Department of Pharmacology, 2016, Doctoral Excellence Award for CWRU School of Medicine, 2018.
Current Position: Post-doctoral Fellow, NYU, Thales Papagiannakopoulos
- 2006-11 **Gina Sizemore (Bernardo)**, Department of Pharmacology
Thesis Title: Discerning the role of FOXA1 in mammary gland development and breast cancer.
Awards: Department of Defense Breast Cancer Research Program Pre-doctoral training fellowship, W81XWH-06-1-0712, 2006-2009; Greenfield Family Travel Award (for best Journal Club of 07/08 school year in Pharmacology at CWRU), 2008; Marcus Singer Poster Award, Biomedical Graduate Student Symposium at CWRU, 2009; Susan G. Komen for the Cure Scholar-in-Training Travel Award to the AACR Advances in Breast Cancer Research Special Conference, 2009; Normal and Abnormal Development Training Grant T32HD007104, 2009; Developmental Biology Retreat outstanding oral presentation award, 2010; The President's Award for best oral presentation, Biomedical Graduate Student Symposium at CWRU, 2010; Graduate Student of the Year in Pharmacology, 2010; Annual Excellence in Research Award, Dept. Pharmacology, 2010; Doctoral Excellence in Pharmacology Award, 2012
Current Position: Assistant Professor, Ohio State University

- 2003-10 **Jennifer Yori**, Department of Pharmacology
Thesis Title: Discerning the role of Krüppel-like Factor 4 in breast cancer.
Award: DOD Breast Cancer Research Program Predoctoral Training Grant DAMD17-03-1-0302 (continuation from M. Landis) 2005-06
Current Position: Medical Science Liaison, Teva Pharmaceutical Industries
- 2003-09 **Marjorie Montanez-Wiscovich**, M.D./Ph.D. student, Department of Pharmacology
Thesis Title: Discerning the role of LMO4 as a global modulator of G2/M cell cycle progression and centrosome cycle in breast cancer cells.
Awards: President's Award for the best oral presentation at the Biomedical Graduate Student Symposium, 2006; Predoctoral NRSA 1F31CA123642, 2006-07; Travel Award to the Endocrine Society Meeting, 2006; Honorable Mention Poster Award for Research Showcase at CWRU, 2008
Current Position: Assistant Professor, Department of Dermatology, University of Florida School of Medicine
- 2002-07 **Jonathan Mosley**, M.D./Ph.D. student, Department of Pharmacology
Thesis Title: The analysis and utilization of global gene expression data for the study and treatment of breast cancer
Awards: State of Ohio Innovation Incentive Fellowship, 2006, Invited participant, NIH student research showcase, 2006
Current Position: Assistant Professor of Medicine, Vanderbilt University School of Medicine
- 2000-05 **Melissa D. Landis**, Department of Pharmacology
Thesis Title: Elucidating molecular mechanisms of ErbB2/Neu-induced mammary tumorigenesis
Awards: Graduate Student of the Year in Pharmacology, 2005; Molecular Therapeutics Training Grant, 2001-03; DOD Breast Cancer Research Program Predoctoral Grant DAMD17-03-1-0302, 2003-05; Travel award to the Endocrine Society Meeting, 2001
Current Position: Medical Science Liaison, Bayer Healthcare
- 2000-05 **Erin L. Milliken**, Department of Pharmacology
Thesis Title: Use of a transgenic mouse model of ovarian hyperstimulation to identify therapeutic targets and mechanisms in hormone-induced mammary cancer
Awards: Graduate Student of the Year in Pharmacology, 2002; Cellular and Molecular Biology Training Grant 2000-02; Travel award to the Endocrine Society Meeting, 2002; Research Oncology Training Grant 2002-03; President's Award for best oral presentation at the Biomedical Graduate Student Symposium, 2003
Current Position: Senior Science Writer, NOVA Research Company, Bethesda, MD

Post-baccalaureate Research Education Program (PREP) Scholars

- 2019-20 Amy Aponte
- 2017-19 Natasha Ingles (MSTP matriculation at CWRU)
Awards: PREP Scholar of the Year, 2018; Outstanding Poster Presentation, Case Comprehensive Cancer Center Annual Retreat, 2018; Outstanding Poster Presentation, Department of Pharmacology Annual Retreat, 2018; Outstanding Oral Presentation, Case PREP Research Day, 2019
- 2016-17 Victoria Osorio (doctoral program matriculation at NYU)
- 2015-16 Myrielis Rivera-Burgos (medical technology matriculation at University of Puerto Rico)
- 2014-15 Erika Ramos (doctoral program matriculation at CWRU)
- 2013-14 Leslie Cuellar (doctoral program matriculation at CWRU)

2012-13 Valery Adorno-Cruz (doctoral program matriculation at CWRU)
2007-08 Carlos DeLeon-Rodriguez (doctoral program matriculation at Albert Einstein Univ.)

M.S. Students

2011-12 Maritza Rosales, Department of Genetics
2009-11 Brad Casali, Department of Pharmacology
Awards: Research Oncology Training Grant 5T32CA059366, 2009; Molecular
Therapeutics Training Grant T32GM008803, 2010
1998-2002 Kristen Lozada, Department of Pharmacology

Undergraduate Students

2019 Katelyn Grenell, Summer Undergraduate Research Program, Dept. Pharmacology
2019 Madeline Jenkins, CanSUR Program, Case CCC
2019 Eduardo Williams, CanSUR Program, Case CCC
2018 Marian Chu, Department of Biochemistry
2018 Nick Latina, Summer Undergraduate Research Program, Dept. Pharmacology
2017- Viviane Finke, Department of Biochemistry
2016-17 Kevin Yang, Department of Biochemistry
2015-18 Jennifer Hoffmann, Department of Biology
2013-16 Garrett Dunlap, Department of Biology, Honors Thesis
2012-13 Kevin Wang, Department of Biology
2011-12 Swati Putcha, Department of Biochemistry
2011 Raechel McKinley, Summer Undergraduate Research Program, Dept.
Pharmacology
2011 Monica Clark, Department of Biomedical Engineering
2007-10 Tope Pedro, Department of Biology; Dept. Pharmacology, SPUR Fellowship, 2008
2010 Ann Marie McCabe, Summer Undergraduate Research Program, Dept.
Pharmacology
2010 Chisom Odoh, Summer Undergraduate Research Program, ACES+
2007 Minakshee Mohanty, Department of Biomedical Engineering
2007 Cara Bradley, Department of Biochemistry, SPUR Fellowship
2004-06 John Poirier, Department of Biology, Honors Thesis, Endocrine Society Summer
Research Fellowship, 2005; First Place in Poster Competition, SOURCE
Undergraduate Research Symposium, 2005; First Place, Michelson Morley
Undergraduate Research Competition, 2006; Second Place SOURCE
research paper competition, 2006
2004 Sophia Sushailo, SURP, Department of Pharmacology
2003-04 Nicole Zadzilka, Department of Biochemistry, Honors Thesis, Howard Hughes
Summer Research Fellowship, 2003
2001-03 Lenka Yunk, Department of Biology, Honors Thesis
2002-03 Nicole Grieselhuber, Department of Biology, Honors Thesis
2002 Hannah Lederman, SURP, Department of Pharmacology
2000-02 Jennifer O'Malley, Department of Biology, Honors Thesis
2000-01 Michele Gandolfi, Department of Biology
1997-99 Deva Rama, Department of Chemistry

High School Students:

2018-19 Kareem King, Charles F. Brush High School (Young Scientist Foundation)
2017 Audrey Dietz, Hawkin High School
2017 Eduardo Williams Medina, Cleveland School of Science and Medicine (Young
Scientist Foundation)
2013 Cashalynn Bolden, Glenville High School (High School Student Enrichment and
Opportunity Program)

2012	Marangely Aponte, James Ford Rhodes High School (High School Student Enrichment and Opportunity Program)
2011	Nana Owusu, Solon High School (High School Student Enrichment and Opportunity Program)
2001-04	Laurel Korb, Hathaway Brown High School

COMMUNITY OUTREACH/SCIENCE ADVOCACY

2019	American Cancer Society, ResearchHERS ambassador
2019	Case Comprehensive Cancer Center lab tours, "From Lab to Life"
2018	Case Cancer Council presentation in Naples, Florida, "Genes and Cancer: What You Are Born with Matters"
2018	Endocrine Society NIH advocacy visits, NCI and CSR
2017	Cleveland Scene Magazine Interview, Scene and Heard: CWRU's Dr. Ruth Keri on Misunderstanding in Cancer Research, Underrepresentation of Women in Science, and NIH funding
2017	Nutrition Action, Center for Science in the Public Interest, Interview on Bisphenol A and Cancer, "BPA: still a big deal"
2016	Capitol Hill Day, Endocrine Society
2016	Endocrine Society-Endo TV interview on NIH funding—YouTube
2015	Endocrine Society Delegate to Rally for Medical Research
2015	Cleveland Science Café, Discussion Leader, Topic: Breast Cancer
2015	Cleveland City Club Forum Panel Discussant "From Science to Cancer Cures: How the Case Comprehensive Cancer Center Makes the City of Cleveland Better"
2014	National Public Radio, WCPN Cleveland Affiliate, Profiled in: "At Case, A Fight for NIH Funding"
2014	Kirtland High School Panel Discussant-STEM Careers
2014,15,16	Capitol Hill Day, Endocrine Society-sponsored meetings with congressional aids
2012	CWRU Medical School Dialogue on Discovery, Topic: Cancer Therapy
2012	Case Comprehensive Cancer Center, Cancer Advisory Panel, Topic: Novel Breast Cancer Therapy
2011,14	High School Student Shadowing, Kirtland High School: Jared Gerry, Matthew Keri, Angela Bracolo, Hannah Kelly, Anna Keri
2010	Cleveland Science Café, Discussion Leader, Topic: Drug Delivery
2006	Cleveland Plain Dealer, Profiled in: "Search for Cure Means Chase for Funding"

CURRENT AND COMPLETED RESEARCH SUPPORT

Total external funding with Keri as PI (as of 12/20/18) = \$10,361,366

This does not include Trainee fellowships, Cancer Center Support Grant, ACS IRG, or grants as Co-I

Current Funding:

Ruth A. Keri, PI (20% effort)

1R01CA213843

"Elucidating and leveraging the mTOR negative feedback pathway in breast cancer"

NIH/NCI

8/1/2017-7/31/2022

\$255,156 Annual Direct Costs

Ruth A. Keri, PI (10% effort)
1R01CA206505
“Targeting BET proteins in triple negative breast cancers”
NIH/NCI
3/14/2016-2/28/2021
\$238,546 Annual Direct Costs

Ruth A. Keri, PI (5% effort)
IRG-91-022-15
“Case CCC Institutional Research Grant”
This grant is to fund junior investigators without national funding and Keri is the PI of the parent grant.
American Cancer Society
3/31/10-12/31/19 (Renewal recommended for funding, NOA expected in October, 2019)
\$450,000 Total Costs for current cycle 2016-19

Stanton L. Gerson, PI
Ruth A. Keri, Associate Director for Basic Research (25% effort)
5P30CA043703
“Comprehensive Cancer Support Grant”
This grant supports the management of the Case Comprehensive Cancer Center
NIH/NCI
09/30/91-03/31/23
\$4,577,864 Annual Direct Costs
Renewed in 2018 with “Exceptional” score

Bryan Webb—F31 Awardee
Ruth Keri—Predoctoral Mentor
1F31CA224809
“Defining the super-enhancer landscape in triple negative breast cancer subtypes”
NIH/NCI
10/1/2017-9/30/2020
\$48,403 Annual Direct Costs

Lindsey Anstine—DoD Breakthrough Fellowship Awardee
Ruth Keri—Postdoctoral Mentor
W81XWH1810455
“Transcriptional repression of aggressive phenotypes of breast cancer”
DoD-Breast Cancer Research Program
9/1/2018-8/31/2021
\$100,000 Annual Direct Costs

Completed Funding:

Sylvia Gayle—F32 Awardee
Ruth Keri—Postdoctoral Mentor
1F32CA210426
“Epigenetically reversing paclitaxel resistance in triple negative breast cancers”
NIH/NCI
3/1/2017-2/28/2018
\$61,866 Annual Direct Costs

Jennifer Sahni—F99/K00 Awardee

Ruth Keri—Predoctoral Mentor

1F99CA212460

“Identifying epigenetic drivers and their targets in aggressive breast and ovarian cancers”

NIH/NCI

9/21/2016-8/31/2018

\$34,398 Annual Direct Costs

Ruth A. Keri, PI (10% effort)

W81XWH-14-1-0354

“An epigenetic regulatory hub in basal breast cancer”

Department of Defense, USAMRMC

Breakthrough Award

9/30/2014-9/29/2017

\$115,299 Annual Direct Costs

Ruth A. Keri, PI (10% effort)

1R21HD081165

“A novel regulator of breast development”

NIH/NICHD

07/01/2014-06/30/2017 (no cost extension)

\$125,000 Annual Direct Costs

Ruth A. Keri, PI (20% effort)

1R01CA154384-01A1

“KLF4 regulation of epithelial/mesenchymal transition in breast cancer”

NIH/NCI

7/1/2011-4/30/2017 (no cost extension)

\$201,275 Annual Direct Costs

Nicole Steinmetz, PI

Ruth A. Keri, Co-PI

1509232

“Improved detection of Ebola through nanomanufacturing of bio-inspired diagnostics”

NSF/CMMI

1/15/2015-12/31/2015

\$99,999 Total Direct Costs

Junran Zhang, PI

Ruth A. Keri, Co-Investigator (2% effort)

1R01CA154625

“The role of NEDD-4 in IGF-1R signaling”

NIH/NCI

08/08/2011-05/31/2016

\$207,500 Annual Direct Costs

Efstathios Karathanasis, PI

Ruth A. Keri, Co-Investigator (8% effort)

1R01CA177716

“Detection of micrometastasis using dual-ligand nanoparticle”

NIH/NCI

07/01/2013-05/31/2018

\$207,500 Annual Direct Costs

Vinod Labhasetwar, PI
Ruth A. Keri, Co-Investigator (5% effort)
5R01CA149359
“Drug resistance in cancer therapy”
NIH/NCI
05/10/2010-3/31/2015
\$239,493 Annual Direct Costs

Ruth A. Keri, PI (15% effort)
2R01CA090398
“Regulation of erbB2/Neu-induced mammary gland cancer”
NIH/NCI
4/1/07-1/31/13
\$702,005 Total direct costs
Supplement for Minority Training (Emhonta Johnson)
3/1/2008-1/31/12
\$136,438 Annual Direct Costs

Ruth A. Keri, PI (10% effort)
W81XWH-11-1-0185
“GABA(A) receptor pi (GABRP) regulation of basal type breast cancer
Department of Defense, USAMRMC
2/1/11-1/30/2013
\$374,932 Total direct costs

Ruth A. Keri, PI
“Follistatin as an inhibitor of metastatic progression in breast cancer”
Case Comprehensive Cancer Center Biorepository Pilot Award
12/1/2010-11/31/2011
\$50,000 Total direct costs

Steven Sizemore, PI—Postdoctoral Traineeship
Ruth A. Keri—Postdoctoral Mentor
W81XWH-09-1-0696
“FoxC1 in basal-type breast cancer”
Department of Defense, USAMRMC
9/15/09-9/14/12
\$225,000 Total direct costs

Ruth A. Keri, PI (10% effort)
W81XWH-09-1-0070
“p120ctn and breast cancer metastases”
Department of Defense, USAMRMC
03/01/2009-02/28/2012
\$375,000 Total direct costs

Melissa Shelton, PI—Postdoctoral Traineeship
Ruth A. Keri—Postdoctoral Mentor
W81XWH-09-1-0558
“LMO4 and estrogen responsiveness”
Department of Defense, USAMRMC
9/1/09-8/31/12
\$209,472 Total direct costs

Ruth A. Keri, PI (10% effort)
W81XWH-08-1-0347
“Identifying the contrasting functions of the forkhead transcription factors FoxA1 and FoxC1 in breast cancer”
Department of Defense, USAMRMC
4/21/2008-4/20/2011
\$300,000 Total direct costs

Ruth A. Keri, PI of Pilot Project (10% effort)
SPN00584 (Pamela Davis, PI)
Clinical and Translational Science Award
“Molecular cartography of HER2-induced bone marrow micrometastases”
6/1/09-5/31/10
\$49,704 Total direct costs

Ruth A. Keri, PI of Pilot Project
Coulter Foundation (Jeff Duerk, PI)
Translational Research
6/1/09-5/31/10
\$25,000 Total direct costs

Gina Bernardo, PI—Predoctoral Traineeship Award
Ruth A. Keri—Mentor
W81XWH-06-1-0712
“Functional interaction between Her2/ErbB2/Neu and Met receptor signaling in breast cancer”
Department of Defense, USAMRMC
8/30/2006-7/31/2009
\$89,097 Total direct costs

Ruth A. Keri, PI of Pilot Award (10% effort)
U54CA116867 (Nathan Berger, PI)
Transdisciplinary Research in Energetics and Cancer (TREC)
“Maternal Obesity and Fetal Patterning of Breast Cancer Risk”
NIH/NCI
10/1/2008-9/31/2009
\$50,000 Total direct costs

Ruth A. Keri, PI (10% effort)
2R01ES015768
“Mammary cancer susceptibility following *in utero* exposure to bisphenol A”
NIH/NIEHS
1/15/07-12/31/09 (1 year no-cost extension)
\$275,000 Total direct costs

Ruth A. Keri, PI (10% effort)
BCTR108306
“Evaluating the role of GKLf/KLF4 in mammary gland development and carcinogenesis”
Susan G. Komen Foundation
5/1/06-4/30/08
\$200,000 Total direct costs

Ruth A. Keri, PI (10% effort)

Case Comprehensive Cancer Center Pilot Project for *In Vivo* Cellular and Molecular Imaging of Cancer, Cancer Therapeutics P50 Working Group

“Forkhead transcription factor regulation of mammary gland development and breast cancer progression”

Case Comprehensive Cancer Center

3/15/07-3/14/08

\$40,000 Total direct costs

Marjorie Montanez-Wiscovich, PI—Ruth L. Kirschstein NRSA Predoctoral Award

Ruth A. Keri—Mentor

1F31CA123642

“Minority predoctoral fellowship program (Evaluating the role of LMO4 in ErbB2-induced breast cancer)”

NIH/NCI

\$29,484 Total direct costs

Ruth A. Keri, PI (10% effort)

W81XH-04-1-0542

“Id2 as an integrator of oncogenic stimuli in breast cancer”

Department of Defense, USAMRMC

7/23/04-7/21/07

\$299,316 Total direct costs

Ruth A. Keri, PI (50% effort)

1 R01CA90398-05

“Hormonal regulation of erbB2-induced mammary gland cancer”

NIH/NCI

3/5/01-2/31/07

\$675,000 Total direct costs for Parent Grant

Administrative supplement for Activities to Promote Research Collaborations (APCR)

Jeffrey L. Duerk, Co-PI

5/03-4/05, \$236,086 Total direct costs

Administrative supplement for Minority Training

9/04-2/06, \$73,942 Total direct costs

\$985,028 Total direct costs for entire project

Ruth A. Keri, PI (25% effort)

DAMD17-01-1-0195

“A transgenic model of ovarian hyperstimulation and mammary cancer predisposition”

Department of Defense, USAMRMC

06/18/01-7/17/04

\$287,986 Total direct costs

Jennifer Yori (initially awarded to Melissa Landis), PI—Pre-doctoral Traineeship Award

Ruth A. Keri—Mentor

DAMD17-03-1-0302

“Elucidating the Molecular Mechanisms that Contribute to Neu/erbB2-Induced Mammary Tumorigenesis”

Department of Defense, USAMRMC

4/28/03-4/27/06

\$83,200 Total direct costs

Fadi Abdul Karim, PI, Ruth A. Keri, Co-PI
Pathology Associates Research Grant
"Identifying the hormones that potentiate erbB2-function in mammary gland tumorigenesis"
University Hospitals of Cleveland
11/1/00-10/31/01
\$10,000 Annual direct costs

Ruth A. Keri, PI
President's Research Initiative
"Genetic basis of hormone-induced mammary cancer"
Case Western Reserve University
11/1/99-6/30/01
\$36,888 Total direct costs

James V.K. Willson, PI; Ruth A. Keri, Project Leader (25% effort)
P30 CA43703 Ireland Cancer Center Core Administrative Supplement
"Ovarian hyperstimulation and mammary cancer predisposition in mice"
NIH/NCI
8/1/00-7/31/01
\$49,936 Total direct costs

Ruth A. Keri, PI
IRG-91-022-06
"LH induction of mammary hyperplasia in mice"
American Cancer Society Institutional Grant
3/1/99-2/28/00
\$15,000 Total direct costs

BIBLIOGRAPHY

Refereed Publications

1. Bokar, J.A., **Keri, R.A.**, Farmerie, T.A., Fenstermaker, R.A., Andersen, B., Hamernik, D.L., Yun, J., Wagner, T., and Nilson, J.H. 1989. Expression of the glycoprotein hormone α -subunit gene in the placenta requires a functional cyclic AMP response element, whereas a different *cis*-acting element mediates pituitary-specific expression. *Mol. Cell. Biol.* **9**: 5113-5122.
2. **Keri, R.A.**, Andersen, B., Kennedy, G., Hamernik, D.L., Clay, C.M., Brace, A.D., Nett, T.M., Notides, A.C., and Nilson, J.H. 1991. Estradiol inhibits transcription of the human glycoprotein hormone alpha subunit gene despite the absence of a high affinity binding site for the estrogen receptor. *Mol. Endocrinol.* **5**:725-733.
3. Kendall, S.K., Saunders, T.L., Jin, L., Lloyd, R.V., Glode, L.M., Nett, T.M., **Keri, R.A.**, Nilson, J.H., and Camper, S.A. 1991. Targeted Ablation of Pituitary Gonadotrophs in Transgenic Mice. *Mol. Endocrinol.* **5**:2025-2036.
4. Hamernik, D.L.*, **Keri, R.A.***, Clay, C.M., Clay, J.N., Sherman, G.B., Sawyer, H.R., Nett, T.M., and Nilson, J.H. 1992. Gonadotrope- and Thyrotrope-Specific Expression of the Human and Bovine Glycoprotein Hormone α -Subunit Genes is Regulated by Distinct *Cis*-Acting Elements. *Mol. Endocrinol.* **6**:1745-1755. *The first two authors have contributed equally to this work.
5. Clay, C.M., **Keri, R.A.**, Finicle, A.B., Heckert, L.L., Hamernik, D.L., Marschke, K.M., Wilson, E.M., French, F.S., and Nilson, J.H. 1993. Transcriptional repression of the glycoprotein hormone α subunit gene by androgen may involve direct binding of androgen receptor to the proximal promoter. *J. Biol. Chem.*, **268**: 13556-13564.
6. **Keri, R.A.**, Wolfe, M.W., Saunders, T.L., Anderson, I., Kendall, S.K., Wagner, T., Yun, J., Gorski, J., Nett, T.M., Camper, S.A., and Nilson, J.H. 1994. The proximal promoter of the bovine LH β subunit

gene confers gonadotrope-specific expression and regulation by GnRH, testosterone, and 17 β -estradiol in transgenic mice. *Mol. Endocrinol.*, **8**:1807-1816.

7. **Keri, R.A.**, and Nilson, J.H. 1996. A Steroidogenic Factor-1 binding site is required for activity of the luteinizing hormone β subunit promoter in gonadotropes of transgenic mice. *J. Biol. Chem.*, **271**:10782-10785. >150 citations.
8. Farmerie, T.A., Abbud, R.A., Budworth, P.B., Clay, C.M., **Keri, R.A.**, McDowell, K.J., Wolfe, M.W., and Nilson, J.H. 1997. Characterization of the equine glycoprotein hormone alpha-subunit gene reveals divergence in the mechanism of pituitary and placental expression. *Biol. Reprod.*, **57**:1104-1114.
9. Mann, R.J., **Keri, R.A.**, and Nilson, J.H. 1999. Transgenic mice with chronically elevated LH are infertile due to anovulation, defects in uterine receptivity, and midgestation pregnancy failure. *Endocrinol.*, **140**:2592-2601.
10. **Keri, R.A.**, Lozada, K.L., Abdul-Karim, F.W., Nadeau, J.H., and Nilson, J.H. 2000. Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition. *Proc. Natl. Acad. Sci. USA*, **97**:383-387.
11. Kero J., Poutanen M., Zhang F.-P., Rahman N., McNicol A.-M., Nilson J.H., **Keri R.A.** and Huhtaniemi I. 2000. Elevated luteinizing hormone (LH) in transgenic mice induces functional LH receptor expression and steroidogenesis in adrenal cortex. *J. Clin. Invest.* **105**:633-641. >150 citations.
12. **Keri, R.A.**, Bachmann, D.J., Behrooz, A., Herr, B.D., Ameduri, R.K., Quirk, C.C. and Nilson, J.H. 2000. An NF-Y binding site is important for basal, but not GnRH stimulated, expression of the luteinizing hormone β subunit gene. *J. Biol. Chem.* **275**:13082-13088.
13. Quirk, C.C., Lozada, K.L., **Keri, R.A.**, and Nilson, J.H. 2001. Basal activity and GnRH responsiveness of the LH β promoter *in vivo* requires a Pitx1 binding site. *Mol. Endocrinol.* **15**:734-746.
14. Hodges, C., Ilagan, A., Jennings, D., **Keri, R.**, Nilson, J., and Hunt, P. 2002. Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation. *Human Reproduction* **17**:1171-1180.
15. Owens, G.E., **Keri, R.A.**, and Nilson, J.H. 2002. Ovulatory surges of hCG prevent hormone-induced granulosa cell tumor formation leading to the identification of tumor-associated changes in the transcriptome. *Mol. Endocrinol.* **16**:1230-1242.
16. Milliken, E.L., Ameduri, R.K., Landis, M.D., Behrooz, A., Abdul-Karim, F.W., and **Keri, R.A.** 2002. Ovarian hyperstimulation by luteinizing hormone leads to mammary gland hyperplasia and cancer predisposition in transgenic mice. *Endocrinol.*, **143**:3671-3680.
17. Kero, J., Savontaus, E., Mikola, M., Pesonen, U., Koulu, M., **Keri, R.A.**, Nilson, J.H., Poutanen, M., and Huhtaniemi, I. 2003. Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion. *Am. J. Physiol. Endocrinol. Metab.* **285**:E812-818.
18. Mikola, M., Kero, J., Nilson, J.H., **Keri, R.A.**, Poutanen, M., and Huhtaniemi, I. 2003. High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin α -subunit promoter/Simian virus 40 T-antigen fusion gene. *Oncogene*, **22**:3269-3278.
19. Knostman, K.A.B., Cho, J.-Y., Ryu, K.-Y., Lin, X., McCubrey, J.A., Hla, T., Liu, C.H., Di Carlo, E., **Keri, R.**, Zhang, M., Hwang, D.Y., Kisseberth, W.C., Capen, C.C., Jhiang, S.M. 2004. Signaling through 3',5'-cyclic AMP and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. *J. Clin. Endocrinol. Metab.*, **89**:5196-5203.
20. Landis, M.D., Seachrist, D.D., Montanez-Wiscovich, M.E., Danielpour, D. and **Keri, R.A.** 2005. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor- β signaling in ErbB2/Neu-induced tumors from transgenic mice. *Oncogene*, **24**:5173-5190.

21. Milliken, E.L., Zhang, X., Flask, C., Duerk, J.L., MacDonald, P.N., and **Keri, R.A.** 2005. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. *Cancer Lett.*, **229**:205-215.
22. Landis, M.D., Seachrist, D.D., Abdul-Karim, F., and **Keri, R.A.** 2006. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. *Oncogene*, **25**:3325-3334.
23. Mosley, J.D. and **Keri, R.A.** 2006. Splice variants of mlAP1 have an enhanced ability to inhibit apoptosis. *Biochem. Biophys. Res. Comm.* **348**:1174-1183.
24. Casadesus, G., Milliken, E.L., Webber, K.M., Bowen, R.L., Lei, Z.M., Rao, C.V., Atwood, C.S., Perry, G. **Keri, R.A.**, and Smith, M.A. 2007. Declines in cognitive performance are associated with increased luteinizing hormone levels in mice. *Mol. Cell. Endocrinol.* **269**:107-111.
25. Mosley, J.D., Poirier, J.T., Seachrist, D.D., Landis, M.D., and **Keri, R.A.** 2007. Rapamycin Inhibits Multiple Stages of c-Neu/ErbB2-induced Tumor Progression in a Transgenic Mouse Model of HER2-Positive Breast Cancer. *Mol. Cancer Ther.* **6**:2188-2197.
26. Milliken, E.L., Lozada, K.L., Johnson, E., Landis, M.D., Seachrist, D.D., Whitten, I., Sutton, A.L.M., Abdul-Karim, F.W., and **Keri, R.A.** 2008. Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer. *Oncogene*. **27**:1759-1766.
27. Mosley, J.D., and **Keri, R.A.** 2008. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. *BMC Med. Gen.* **1**:11.
28. Mosley, J.D. and **Keri, R.A.** 2009. Intrinsic bias in breast cancer gene expression data sets. *BMC Cancer*, **9**:214.
29. Peters, G.A., Seachrist, D.D., **Keri, R.A.**, and Sen, G.C. 2009. The double-stranded RNA-binding protein, PACT, is required for postnatal anterior pituitary development. *Proc. Natl. Acad. Sci.*, **106**:10696-10701.
30. Montanez-Wiscovich, M.E., Seachrist, D.D., Landis, M.D., Visvader, J., Andersen, B., and **Keri, R.A.**, 2009. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. *Oncogene*, **28**:3608-3618.
31. Yori, J.L., Johnson, E., Zhou, G., Jain, M.K., and **Keri, R.A.** 2010. Kruppel-like Factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. *J. Biol. Chem.*, **285**:16854-16863.
32. Bernardo, G., Lozada, K.L., Mosley, J.D., Miedler, J.D., Harburg, G., Asselin-Labat, M.-L., Hewitt, S.C., Godwin, A.K., Korach, K.S., Visvader, J.E., Kaestner, K.H., Abdul-Karim, F.W., Montano, M.M., and **Keri, R.A.** 2010. FoxA1 is an essential determinant of ER-alpha expression and mammary ductal morphogenesis. *Development*, **137**:2045-2054, *Featured on cover.* >150 citations.
33. Johnson, E., Seachrist, D.D., DeLeon-Rodriguez, C., Lozada, K.L., Miedler, J., Abdul-Karim, F.W., and **Keri, R.A.** 2010. HER2/ErbB2-Induced breast cancer cell migration and invasion requires p120 catenin activation of Rac1 and Cdc42. *J. Biol. Chem.*, **285**:29491-29501. *Featured by F1000.*
34. Montanez-Wiscovich, M.E., Shelton, M.D., Seachrist, D.D., Lozada, K.L., Johnson, E., Miedler, J., Abdul-Karim, F.W., Visvader, J.E., and **Keri, R.A.** 2010. Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells. *J. Pathol.*, **222**:271-281.
35. Yori, J.L., Seachrist, D.D., Johnson, E., Lozada, K.L., Abdul-Karim, F.W., Chodosh, L.A., Schiemann, W. P., and **Keri, R.A.** 2011. Kruppel-like factor 4 Inhibits Tumorigenic Progression and Metastases in a Mouse Model of Breast Cancer. *Neoplasia*, **13**:601-610. *Featured on cover.*
36. Weber Lozada, K., and **Keri, R.A.** 2011. Bisphenol A increases mammary cancer risk in two distinct murine models of breast cancer. *Biol. Reproduction*, **85**:490-497. *Featured by F1000 Medicine.*

37. Beach, J.R., Hussey, G.S., Miller, T.E., Chaudhury, A., Patel, P., Monslow, J., Zheng, Q., **Keri, R.A.**, Reizes, O., Bresnick, A.R., Howe, P.H., and Egelhoff, T.T. 2011. Myosin II Isoform switching mediates invasiveness following TGF β -induced epithelial-mesenchymal transition. *Proc. Natl. Acad. Sci.*, **108**: 17991-17996.
38. Peiris, P.M., Bauer, L., Troy, R., Tran, E., Pansky, J., Doolittle, E., Schmidt, E., Hayden, E., Mayer, A., **Keri, R.A.**, Griswold, M.A., and Karathanasis, E. 2012. Enhanced delivery of chemotherapy to tumors using a multi-component nanochain with radiofrequency-tunable drug release. *ACS Nano*, **6**:4157-4168.
39. Sizemore, S.T. and **Keri, R.A.** 2012. The forkhead transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression. *J. Biol. Chem.*, **287**:24631-40.
40. Seachrist, D.D., Johnson, E., Magee, C., Clay, C.M., Graham, J.K., Veeramachaneni, D.N.R., and **Keri, R.A.**, 2012. Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts. *Biol. Reprod.*, **87**:41.
41. Peiris, P., Toy, R., Doolittle, E., Pansky, J., Abramowshi, A., Tam, M., Vicente, P., Tran, E., Hayden, E., Camann, A., Erokwu, B., Berman, Z., Wilson, D., Baskaran, H., Flask, C., **Keri, R.A.**, Karathanasis, E. 2012. Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. *ACS Nano*, **6**:8783-8795.
42. Bernardo, G.M., Bebek, G., Ginther, C.L., Sizemore, S.T., Lozada, K.L., Miedler, J.D., Anderson, L.A., Godwin, A.K., Abdul-Karim, F.W., Slamon, D.J., and **Keri, R.A.** 2013. FOXA1 actively represses the molecular phenotype of basal breast cancer cells. *Oncogene*, **32**:554-563.
43. Asrani, K., **Keri, R.A.**, Galidsteo, R., Brown, S., Horvat, S., Ghosh, A., Tran, N., Winkles, J. 2013. The HER2- and heregulin β 1 (HRG)-inducible TNFR superfamily member Fn14 promotes HER-driven cell migration, invasion and MMP9 expression. *Mol. Cancer Res.*, **11**:393-404.
44. Sizemore, G.M., Sizemore, S.T., Pal, B., Booth, C.N., Abdul-Karim, F.W., Kume, T., **Keri, R.A.** 2013. FOXC1 is enriched in the mammary luminal progenitor population, but is not necessary for mammary ductal morphogenesis. *Biol. Reprod.*, **89**:10.
45. Peiris, P.M., Tam, M., Vicente, P., Abramowski, A., Toy, R., Bauer, L., Mayer, A., Pansky, J., Doolittle, E., Tucci, S., Schmidt, E., Shoup, C., Rao, S., Murray, K., Gopalakrishnan, R., **Keri, R.A.**, Basilion, J.P., Griswold, M.A., and Karathanasis, E. 2014. On-command drug release from nanochains inhibits growth of breast tumors. *Pharm. Res.*, **31**:1460-1468.
46. Shukla, S., Wen, A.M., Ayat, N.R., Commandeur, U., Gopalkrishnan, R., Broome, A.-M., Lozada, K.W., **Keri, R.A.**, and Steinmetz, N.F. 2014. Biodistribution and clearance of a filamentous plant virus in healthy and tumor-bearing mice. *Nanomedicine*, **9**:221-235.
47. Sizemore, S.T., Sizemore, G.M., Booth, C.N., Thompson, C.L., Silverman, P., Bebek, G., Abdul-Karim, F.W., Avril, S., and **Keri, R.A.** 2014. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. 2014. *Breast Cancer Res. Treat.*, **146**:25-40.
48. Yori, J.L., Lozada, K.L., Seachrist, D.D., Booth, C., Abdul-Karim, F.W., Flask, C., and **Keri, R.A.** 2014. Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. *Cancer Research*, **74**:4762-4771.
49. Sizemore, G.M., Sizemore, S.T., and **Keri, R.A.** 2014. GABRP regulates ERK1/2 activity, cytokeratin expression and migration in basal-like breast cancer cells. *J. Biol. Chem.*, **289**:24102-24113.
50. Han, X., Zhang, L., Chung, J., Pozo, F.M., Seachrist, D., Jacobberger, J., **Keri, R.A.**, Gilmore, H., and Zhang, Y. 2014. UBCH7 regulates 53BP1 stability and DSB repair. *Proc. Natl. Acad. Sci.*, **111**:17456-17461.

51. Yehia, L., Niazi, F., Ni, Y., Ngeow, J., Sankunny, M., Liu, Z., Mester, J.L., **Keri, R.A.**, Zhang, B., and Eng, C. 2015. *SEC23B* germline heterozygous mutations cause ER stress resistance and predisposition to hereditary and apparently sporadic cancers. *Am. J. Hum. Genetics*, **97**:661-676.
52. Lam, P. Gulati, N.M., Stewart, P.L., **Keri, R.A.**, and Steinmetz, N.F. 2016. Bioengineering of Tobacco Mosaic Virus to create a non-infectious positive control for Ebola diagnostic assays. *Sci. Rep.*, **6**:23803.
53. Sahni, J.M., Gayle, S.S., Weber-Bonk, K.L., Cuellar Vite, L., Yori, J.L., Webb, B., Ramos, E.K., Seachrist, D.D., Landis, M.D., Chang, J.C., Bradner, J.E., Bebek, G., Summers, M.K., and **Keri, R.A.** 2016. BET protein inhibitors induce mitotic catastrophe in triple negative breast cancer. *J. Biol. Chem.*, **291**:23756-23768.
54. Morrison, C.D., Allington, T.M., Thompson, C.L., Gilmore, H.L., Chang, J.C., **Keri, R.A.**, and Schiemann, W.P. 2016. c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. *Oncotarget*, **8**:72777-72794.
55. Cohen, A.J., Saiakhova, A., Corradin, O., Luppino, J., Lovrenert, K., Bartels, C., Morrow, J.J., Mack, S., Dhillon, G., Beard, L., Myeroff, L., Kalady, M., Willis, J., Bradner, J., **Keri, R.A.**, Berger, N.A., Pruett-Miller, S.M., Markowitz, S.D., and Scacheri, P.C. 2017. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. *Nat. Comm.*, **8**:14400.
56. Mayca Pozo, F., Tang, J., Bonk, K.W., **Keri, R.A.**, Yao, Z, and Zhang, Y. Regulatory crosstalk determines the cellular levels of 53BP1, a critical factor in DNA repair. 2017. *J. Biol. Chem.*, **292**: 5992-6003.
57. Seachrist, D.D., Sizemore, S.T., Johnson, E., Abdul-Karim, F.W., Weber Bonk, K.L., and **Keri, R.A.** 2017. Follistatin is a metastasis suppressor in a mouse model of HER2 positive breast cancer. *Breast Can. Res.*, **19**:66.
58. Morrison, C.D., Chang, J.C., **Keri, R.A.**, and Schiemann, W.P. 2017. Mutant p53 dictates the oncogenic activity of c-Abl in triple negative breast cancers. *Cell Death and Disease*, **8**:e2899.
59. Sahni, J.M., Gayle, S.S., Webb, B.M., Weber-Bonk, K.L., Seachrist, D.D., Singh, S., Sizemore, S.T., Restrepo, N.A., Bebek, G., Scacheri, P.C., Varadan, V., Summers, M.K., and **Keri, R.A.** 2017. Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors. *Cancer Research*, **77**:5395-5408.
60. Lam, P., **Keri, R.A.**, and Steinmetz, N.F. 2017. A bioengineered positive control for rapid detection of *Ebola* virus by reverse transcription loop-mediated isothermal amplification (RT-LAMP). *ACS Biomaterials Science and Engineering*, **3**:452-459.
61. Tsung, K., Thompson, C.L., Knight, J.M., Maximuk, S., Sadri, N., Gilmore, H., **Keri, R.A.**, Vinayak, S., Harris, L., and Silverman, P. 2018. A breast multidisciplinary genomic tumor board is feasible and can provide timely and impactful recommendations. *Breast J.*, **24**:676-677.
62. Yang, X., Pan, Y., Qiu, Z., Du, Z., Zhang, Y., Fa, P., Gorityala, S., Ma, D., Li, S., Chen, C., Wang, J., Yan, C., Xu, Y, **Ruth, K.**, Ma, Z., and Zhang, J. 2018. RNF126 as a biomarker of poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells. *Clin. Cancer Res.*, **24**:1629-1643.
63. Hashemi-Sadrei, N., Muller-Greven, G.M., Ulasov, I., Downs-Kelly, E., Burgett, M.E., Weil, R.J., Du, L., Prayson, R.A., Chao, S., Budd, T.G., Kar, N., Barnholtz-Sloan, J., Nowacki, A.S., **Keri, R.A.**, and Gladson, C.L. 2018. Expression of autophagy-related proteins in metastatic breast cancer to the brain. *J. Neurooncol.*, **140**:237-248.
64. Gayle, S.S., Sahni, J.M., Webb, B., Weber-Bonk, K.L., Shively, M.S., Spina, R., Bar, E.E., Summers, M.K., and **Keri, R.A.** 2019. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. *J. Biol. Chem.*, **294**:875-886.

65. Thakur, V., Zhang, K., Savadelis, A., Zmina, P., Bonk, K.W., Abdul-Karim, F., **Keri, R.A.**, and Bedogni, B. 2019. The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer. *Cancer Lett.*, **443**:115-124.
66. Shukla, S., Jandzinski, M., Wang, C., Gong, X., Weber-Bonk, K., **Keri, R.A.**, and Steinmetz, N.F. 2019. A viral nanoparticle cancer vaccine delays tumor progression and prolongs survival in tumor mouse models. *Adv. Therap.* 1800139.
67. Liao, P., Yori, J.L., **Keri, R.A.**, Koyuturk, M., Barnholtz-Sloan, J.S. 2019. Inference of kinase activity using *in silico* prediction scores. *Submitted*.
68. Sizemore, S.T., Sizemore, G.M., and **Keri, R.A.** 2019. Repression of insulin-like growth factor binding protein 5 (IGFBP5) by forkhead box transcription factor C1 (FOXC1) is required for the viability of basal-like breast cancer cells and is prognostic of response to chemotherapy. *Submitted*.
69. Adorno-Cruz, V., Hoffmann, A.D., Liu, X., **Keri, R.A.**, and Liu, H. 2019. ITGA2 is a target of miR-206 in promoting stemness and lung metastasis of triple negative breast cancer. *Submitted*.
70. Turaga, S.M., Silver, D.J., Bayik, D., Paouri, E., Borjini, N., Peng, S., Naik, U., **Keri, R.A.**, Conner, J., Barnholtz-Sloan, J.S., Rubin, J.B., Berens, M., Davalos, D., Lathia, J.D., 2019, JAM-A functions as a female microglial tumor suppressor in glioblastoma. *Submitted*.
71. Roberts, M.S., Sahni, J.M., Schrock, M.S., Piemonte, K.M., Weber-Bonk, K., Seachrist, D.D., Anstine, L.J., Singh, S., Sizemore, S.T., Varadan, V., Summers, M.K., **Keri, R.A.**, 2019. Leveraging the LIN9/NEK2 pathway to overcome taxane resistance in triple negative breast cancer. *Submitted*.
72. Roberts, M.D., Finke, V.S., Anstine, L.J., Webb, B.M., Weber-Bonk, K., Seachrist, D.D., and **Keri, R.A.**, KLF4 dictates erlotinib sensitivity in breast cancer cells through transcriptional repression of epidermal growth factor receptor. 2019. *To be submitted in September, 2019*.
73. Seachrist, D.D., Hannigan, M.M., Ingles, N.N., Anstine, L.J., Webb, B. Weber-Bonk, K., Guo, Z., Yu, P., Singh, S., Varadan, C., Licatalosi, D.D., **Keri, R.A.**, A BCL11A-regulated splicing program drives invasion and metastatic in triple negative breast cancer. 2019. *To be submitted in October, 2019*.

Review Articles

1. Nilson, J.H., Bokar, J.A., Andersen, B.A., Bohinski, R., Kennedy, G., **Keri, R.A.**, Farmerie, T.A., and Fenstermaker, R.A. 1989. CRE-binding proteins interact cooperatively to enhance placental-specific expression of the glycoprotein hormone alpha-subunit gene. *N.Y. Acad. Sci.* **564**: 77-85.
2. Nilson, J.H., Bokar, J.A., Clay, C.M., Farmerie, T.A., Fenstermaker, R.A., Hamernik, D.L., and **Keri, R.A.** 1991. Different combinations of regulatory elements may explain why placenta-specific expression of the glycoprotein hormone α -subunit gene occurs only in primates and horses. *Biol. Reprod.* **44**:231-237.
3. **Keri, R.A.**, Andersen, B., Kennedy, G.C., Hamernik, D.L., Nilson, J.H. 1992. Estradiol inhibits expression of the human glycoprotein hormone alpha subunit gene through an ERE-independent mechanism. *in: Follicle Stimulating Hormone: Regulation of secretion and Molecular Mechanisms of Action*, ed. M. Hunzicker-Dunn and N.B. Schwartz, Raven Press, Serono Symposia, USA.
4. Clay, C.M., **Keri, R.A.**, Hamernik, D.L., Heckert, L.L., and Nilson, J.H. 1994. Endocrine regulation of glycoprotein hormone alpha subunit gene expression in transgenic mice. *in: Glycoprotein Hormones: Structure, Function, and Clinical Implications*, ed. J.W. Lustbader, D. Puett, and R.W. Ruddon, Raven Press, Serono Symposia, USA.
5. Camper, S.A., Saunders, T.L., Kendall, S.K., **Keri, R.A.**, Seasholtz, A.F., Gordon, D.F., Birkmeier, T.S., Keegan, C.E., Karolyi, I.J., Roller, M.L., Burrows, H.L., and Samuelson, L.C. 1995. Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene functions. *Biol. Reprod.* **52**:246-257.

6. Nilson, J.H., Abbud, R.A., **Keri, R.A.**, and Quirk, C.C. 2000. Chronic hypersecretion of LH in transgenic mice disrupts ovarian and pituitary function with some effects modified by genetic background. *Recent Prog. Horm. Res.*, **55**:69-91.
7. Mann, R.J., **Keri, R.A.**, and Nilson, J.H. 2003. Consequences of elevated LH on diverse physiological systems: use of the LH-CTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology. *Recent Prog. Horm. Res.*, **58**:343-375.
8. **Keri, R.A.**, Ho, S.-M., Hunt, P.A., Knudsen, K.E., Soto, A.M., and Prins, G. 2007. An Evaluation of Evidence for the Carcinogenic Activity of Bisphenol A. *Reprod. Toxicol.*, **24**:240-252. >250 citations.
9. Sutton, A. and **Keri, R.A.** 2007. The pleiotropic effects of excessive LH secretion in transgenic mice. *Semin. Reprod. Med.*, **25**:360-367.
10. vom Saal, F.S., Akingbemi, B.T., Belcher, S.M., Birnbaum, L.S., Crain, D.A., Eriksen, M., Guillette, L.J., Hauser, R., Heindel, J.J., Ho, S.-M., Iguchi, T., Jobling, S., Kanno, J., **Keri, R.A.**, Knudsen, K.E., LeBlanc, G.A., Marcus, M., McLachlan, J.A., Myers, J.P., Nadal, A., Newbold, R.R., Olea, N., Prins, G., Richter, C.A., Rubin, B.S., Sonnenschein, C., Soto, A.M., Talsness, C.E., Vandenberg, L.N., Walsen-Kuntz, D.R., Watson, C.S., Welshons, W.V., Wetherill, Y., Zoeller, R.T. 2007. Chapel Hill bisphenol A expert panel consensus statement: Integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. *Reprod. Toxicol.*, **24**:131-138. >650 citations.
11. Bernardo, G., and **Keri, R.A.** 2012. FOXA1: a transcription factor with paralleling functions in development and cancer. *Biosci. Rep.*, **32**:113-30. *Invited review.*
12. Seachrist, D.D., Bonk, K.W., Ho, S.-M., Prins, G.S., Soto, A.M., Walker, C.L., **Keri, R.A.** 2015. A review of the carcinogenic potential of bisphenol A. *Reprod. Toxicol.*, **59**:167-182.
13. Gayle, S.S., Sahni, J.M., and **Keri, R.A.** 2017. BETi induction of mitotic catastrophe: towing the LIN9. *Oncoscience*, **4**:9-10. *Invited commentary.*
14. Sahni, J.M. and **Keri, R.A.** 2018. Targeting bromodomain and extraterminal proteins in breast cancer. *Pharm. Res.*, **129**:156-176. *Invited review.*
15. Seachrist, D.D. and **Keri, R.A.** 2019. The activin social network: activin, inhibin, and follistatin in breast development and cancer. *Endocrinology*, **160**: 1091-1110. *Invited review.*
16. Anstine, L.J. and **Keri, R.A.** 2019. A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis. *J. Cancer Met. Treat.*, *in press.* *Invited review.*

Textbook Chapters

1. Nilson, J.H., **Keri, R.A.**, and Reed, D.K. 1995. Transgenic mice provide useful paradigms for studies in molecular endocrinology. *in: Molecular Endocrinology: Basic Concepts and Clinical Correlations*, ed. B. Weintraub, Raven Press.
2. **Keri, R.A.** and Nilson, J.H. 2001. Glycoprotein Hormones: Transgenic Mice as Tools to Study Regulation and Function. *in: Transgenics in Endocrinology*, ed. M. Matzuk, R. Kumar, and C. Brown, Humana Press, pp. 261-295.
3. Owens, G.E., **Keri, R.A.**, and Nilson, J.H. 2001. LH Hypersecreting Mice: A Model for Ovarian Granulosa Cell Tumors. *in: Transgenic Models in Endocrinology*, ed. M.G. Castro, Kluwer Academic Press, pp. 59-78.
4. **Keri, R.A.** 2006. Transgenic Technology in Endocrinology. *In: Endocrinology, 5th ed.*, ed. L.J. DeGroot and J.L. Jameson, W.B. Saunders Co.
5. **Keri, R.A.** and Siegel, R.E. 2009. Transgenic and Genetic Animal Models. *In: Hormones, Brain and Behavior, 2nd ed.*, ed. R.T. Rubin and D. Pfaff, Elsevier.

6. Seachrist, D., Donaubauer, E., and **Keri, R.A.** 2018. Hypothalamic-Pituitary-Mammary Gland (HPM) Axis. *In: Encyclopedia of Reproduction vol. 2, Female Reproduction*, ed. Spencer and Flaws.
7. **Keri, R.A.**, Distelhorst, C.W., Sharifi, N., and Berger, N.A. 2019. Hormonal Effects on Tumors. ed. G. Litwack, *In: Hormonal Signaling in Biology and Medicine*, in press.

Educational Methods Manuscripts

1. Kim, P.Y., Allbritton, D.W., **Keri, R.A.**, Mieyal, J.J., Wilson-Delfosse, A.L. 2010. Creation of an online curriculum to introduce and supplement the learning of pharmacology in a problem-based learning/lecture hybrid curriculum. *Int. Assoc. Med. Sci. Educ.*, **202**:98-106.
2. Kim, PY, Allbritton, DW, Keri, RA., Mieyal, JJ, and Wilson-Delfosse, AL. 2015. Supplemental Online Pharmacology Modules Increase Recognition and Production Memory in a PBL Curriculum. *Med. Sci. Educ.* **25**:261-269.

EXTERNAL REFEREES

Kay-Uwe Wagner, Ph.D. (wagnerk@karmanos.org)
 (313) 578-4334
 Lloyd and Marilyn Smith Endowed Chair for Breast Cancer Research
 Professor of Oncology
 Barbara Ann Karmanos Cancer Institute
 Wayne State University School of Medicine

Jennifer Richer, Ph.D. (jennifer.richer@ucdenver.edu)
 (303) 724-3735
 Professor of Pathology
 Co-Director Cancer Pathology Core
 University of Colorado School of Medicine

Kerry Burnstein, Ph.D. (kburnstein@med.miami.edu)
 (305) 243-3299
 Professor and Chair, Molecular and Cellular Pharmacology
 Associate Director for Education and Training
 Sylvester Comprehensive Cancer Center
 University of Miami School of Medicine

Michael Ostrowski, Ph.D. (ostrowsk@musc.edu)
 (843) 792-5012
 WH Folk Endowed Chair in Experimental Oncology
 Professor and Vice Chair of Biochemistry and Molecular Biology
 W.H. Folk Professor in Experimental Oncology
 Medical University of South Carolina

INTERNAL REFEREES

Stanton Gerson, MD (slg5@case.edu)
 216-368-1994
 Director, Case Comprehensive Cancer Center
 Director, National Center for Regenerative Medicine
 Case Western Reserve University School of Medicine

Clifford Harding, MD, Ph.D. (cvh3@case.edu)
 216-368-3611
 Joseph R. Kahn Professor and Chair of Pathology
 School of Medicine
 Case Western Reserve University

Mukesh Jain, MD (mukesh.jain@case.edu)
216-368-2618
Chief Scientific Officer
Harrington Discovery Institute, University Hospitals of Cleveland
Professor of Medicine, Case Western Reserve University